University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln
Papers in Veterinary and Biomedical Science

Veterinary and Biomedical Sciences,
Department of

2-9-1999

NUCLEOTIDE SEQUENCES FOR DETECTION OF SERPULINA
HYODYSENTERIAE
Gerald E. Duhamel
University of Nebraska- Lincoln

Robert Elder
University of Nebraska- Lincoln

Follow this and additional works at: https://digitalcommons.unl.edu/vetscipapers
Part of the Biochemistry, Biophysics, and Structural Biology Commons, Cell and Developmental
Biology Commons, Immunology and Infectious Disease Commons, Medical Sciences Commons,
Veterinary Microbiology and Immunobiology Commons, and the Veterinary Pathology and Pathobiology
Commons

Duhamel, Gerald E. and Elder, Robert, "NUCLEOTIDE SEQUENCES FOR DETECTION OF SERPULINA
HYODYSENTERIAE" (1999). Papers in Veterinary and Biomedical Science. 342.
https://digitalcommons.unl.edu/vetscipapers/342

This Article is brought to you for free and open access by the Veterinary and Biomedical Sciences, Department of at
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Papers in Veterinary and
Biomedical Science by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.

USOO586963OA

United States Patent (19)

11 Patent Number:
(45) Date of Patent:

Duhamel et al.
DETECTION OF SERPULINA
HYODYSENTERIAE

75 Inventors: Gerald E. Duhamel; Robert Elder,
both of Lincoln, Nebr.

73 Assignee: Board of Regents, University of
Nebraska Lincoln, Lincoln, Nebr.

62 Division of Ser. No. 252,492, Jun. 1, 1994.
51) Int. Cl. .......................... C07H 21/02; CO7H 21/04;
C12O 1/68; C12P 19/34

52

U.S. Cl. ......................... 536/22.1; 536/231; 536/243;
536/24.31; 536/24.32; 536/24.33; 435/6;

58

Field of Search .............................. 435/6, 91.1, 91.2,
435/91.21; 536/22.1, 23.1, 24.3, 24.31,

435/91.2

24.32, 24.33
References Cited
U.S. PATENT DOCUMENTS

4,469,672 9/1984 Harris ........................................ 424/23
4,683.202 7/1987 Mullins.

4,748,019 5/1988 Lysons.
4,764,370 8/1988 Fields et al..
4,818,680 4/1989 Collins et al..

4,851,331 7/1989 Vary et al..
3/1991 Glisson et al..
7/1991 Jensen et al. ............................... 435/6
3/1994 Atlas et al..

5,306,616 4/1994 Lupski et al..
FOREIGN PATENT DOCUMENTS

282965 9/1988 European Pat. Off..
350715 1/1990 European Pat. Off..
WO 88/04778
WO 90/O2565
WO 91/04036

Chatfield et al., “Identification of the Major Antigens of
Treponema hyodysenteriae and Comparison with Those of
Treponema innocens,” Inf & Immun., 56: 1070–1075

(1988).

Chenngappa et al., “Laboratory Procedures for the Diagno
sis of Swine Dysentery,” Report of the Committee on Swine
Dysentery, American ASSociation of Veterinary Laboratory
Diagnosticians, Committee on Swine Dysentery, Aug.

(1989).
Chien et al., J. Bacteriol, 127:1550 (1976).
Combs et al., Res. Vet. Sci., 50:286-289 (1991).
Curtiss III et al., Infection and Immunity, 55:3035 (1987).
Cwyk et al., Arch. Microbiol., 122:231-239 (1979).

21 Appl. No.: 727,126
22 Filed:
Oct. 8, 1996
Related U.S. Application Data

4,999,191
5,034,315
5,298,392

Feb. 9, 1999

Caputa et al., J. Clin. Microbiol., 29:2418–2413 (1991).

54) NUCLEOTIDE SEQUENCES FOR

56)

5,869,630

6/1988 WIPO.
3/1990 WIPO.
4/1991 WIPO.
OTHER PUBLICATIONS

Achacha et al., J. Vet. Diag. Invest., 3:211-214 (1991).
Adachi et al., Zentralbl. Bakteriol., 245:527 (1979).
Baum et al., Infect. Immun., 25:792–796 (1979).

Bei et al., “Amplification of Nucleic Acids by Polymerase

Chain Reaction (PCR) and Other Methods and Their Appli
cations”, Critic. Rev. Biochem. Mol. Biol., 26(3/4):301-334
(1991).
Belanger et al., J. Clin. Microbiol., 29:1727–1729 (1991).
Bio/Tech, 6:693 (1988).
Boyden et al., “Cloning and Characterization of Treponema
hyodysenteriae Antigens and Protection in a CF-1 Mouse
Model by Immunization with a Cloned Endoflagellar Anti

gen.” Infect. Immun., 57:3808-3815 (1989).
Boeckman, “New Swine Dysentery Vaccines May be Just
Around the Corner,” Swine Practitioner at pages 4-6, Jan.,

Dettori et al., “Molecular Cloning and Characterization of
DNA from Human Intestinal Spirochetes,” Europ. J. Epi

demiol., 8(2): 198-205 (1992).
Dougan et al., J. Infec. Dis., 158:1329 (1988).
Duhamel et al., “Serodiagnosis of Swine Dysentery Using
Recombinant Proteins from Treponema Hyodysenteriae,”
Nebraska Veterinary Science Newsletter, 19:3-4, Jun. 1990.
Duhamel et al., “Update on Prevention and Control of Swine
Dysentery, 31st George A. Young Swine Conference and
Annual Nebraska SPF Swine Conference, Lincoln, NE, at

pp. 7-20, Aug. 13-14 (1990).

Duhamel et al., “Freedom From Dysentery”, Swine Practi
tioner, at pp. 4-5, 8, and 10, Sep. 1990.
Duhamel et al., “Application to Restriction Length Fragment
Length Polymorphism Typing to Epidemiological Tracing of

Serpulina (Treponema) hyodysenteriae,”, Proc. 12th Int.
Cong. Pig. Vet. Soc., The Hague, Netherlands, vol. 1, p. 276

(1992).
Duhamel et al., J. Vet. Diagn. Invest., 4:285–292 (1992).
Duhamel et al., “Herd Health: Swine Dysentery Probe,
Promising Cleanup Tool.” National Hog Farmer, pp. 48-50,
Dec. 15, 1993.

Edwards et al., J. Bacteriol., 170:3991 (1988).
Elder et al., “Rapid Identification of Serpulina hyodysente
riae By Polymerase Chain Reaction,” 53rd Annual North
Central Branch Meeting, American Society for Microbiol

ogy, Oct. 28–30, at page 21 (1993).
(List continued on next page.)

Primary Examiner Stephanie W. Zitomer
Assistant Examiner Jeffrey Fredman
Attorney, Agent, or Firm-Suiter & Associates PC
57

ABSTRACT

The invention provides a method for detecting the presence
of Serpulina hyOdysenteriae in a biological Sample, an
oligonucleotide primer and an S. hyodysenteriae-specific
oligonucleotide probe useful in that method, and an article
of manufacture that contains the primers and/or probe. Also
provided are an about 2.3-kb DNA fragment derived from
genomic DNA of S. hyodysenteriae and encoding for an
about 56 kDa polypeptide, a recombinant expression vector
containing the DNA fragment, the 56 kDa polypeptide and
a monoclonal antibody reactive with the peptide, and a
method of assaying for antibodies reactive with the 56 kDa
peptide.

1994.

Burrows et al., Vet. Rec., 108:187-189 (1981).

17 Claims, 6 Drawing Sheets

5,869,630
Page 2
OTHER PUBLICATIONS

Elder et al., “Rapid Detection of Serpulina hyodysenteriae in
Diagnostic Specimens By PCR,” J. Clin. Microbiol.,

32:1497 (1994).
Fisher et al., Am. J. Vet. Res., 46:450–455 (1981).

Fisher et al., “Development and Evaluation of a Whole Cell
ELISA for Detection of Serum Antibodies to Treponema
hyodysenteriae in Swine,' Abstract No. 70, 71st Conference

of Research Workers in Animal Disease, Nov. 5-6 (1990).

Flores et al., “Identification of Human Rotavirus Serotype
by Hybridization to Polymerase Chain Reaction-Generated
Probes Derived from a Hyperdivergent Region of the Gene
Encoding Outer Capsid Protein VP7,” J. Virol.,

64:4021–4024 (1990).

Gabe et al., “Molecular Analysis of the vSpA-H Genes
Which Comprise a Multigene Family Encoding a 39-kDa
Variable Surface Protein from Serpulina hyodysenteriae,”
Abstract D156, 94th ASM General Meeting, May 23–27,
1994.

Hampson et al., Epidemiol. Infect., 103:275 (1989).
Harris et al., Diseases of Swine, 7th ed., Iowa State Univer

sity Press (Ames, IA), at pp. 599–616 (1992).
Hopp et al., Mol. Immunol., 20:483 (1983).
Hornich et al., in Vet. Med., 24:29 (1979).
Hugo et al., J. Clin. Microbiol., 25:26-30 (1987).
Hunter et al., Vet. Rec., 104:383–384 (1979).

Islam et al., “Detection of Shigella dysenteriae Type 1 and
Shigella flexneri Feces by Immunomagnetic Isolation and
Polymerase Chain Reaction,” J. Clin. Micro, 30:2801-2806

(1992).
Jenkins, Am. J. Vet. Res., 41:338 (1980).
Jenkins et al., Vet. Immunological Immunopathology, 2:19
(1981).
Jenkins et al., Brit. Vet. Journal, 145:565 (1989).

Jensen et al., “Detection and Identification of Treponema
hyodysenteriae by Using Oligodeoxynucleotide Probes
Complementary to 16S rRNA,” J. Clin. Microbiol.,

28:2717–2721 (1990).
Joens et al., Vet. Records, 106:245 (1980).

Joens et al., “Molecular Characterization of Proteins from

Porcine Spirochetes”, Infect. Imm., 54:893–896 (1986).
Jones et al., J. Clin. Microbiol., 24:1071-1074 (1986).
Judd et al., Appl. Env: Microbiol., 59: 1702 (1993).

Lory, J. Bacteriol., 174:3423–3428 (1992).

Luneberg et al., “Detection of Mycoplasma pneumoniae by
Polymerase Chain Reaction and Nonradioactive Hybridiza

tion in Microtiter Plates,” J. Clin. Micro. 31:1035–1094

(1993).
Lymbery et al., Vet. Microbiol., 22:89-99 (1990).
Lysons, Vet. Rec., 129:314-315 (1991).
Mapother et al., J. Clin. Micro, 22:161-164 (1985).
Mowat et al., Immunology Today, 12:383 (1991).
Muir et al., “Cloning and Expression of a Serpula (Tre
pOnema) hyodysenteriae Hemolysin Gene, Infect. Immun.,
60:529–535 (1992).
Mullis et al., Methods Enzymol., 155:335 (1987).

Norby, “Veterinary Scientists Hope to Break Swine Dysen
tery Transmission Cycle,” Research Nebraska at pages
16–17, Sep., 1993.

Owen, Iowa State J. Res., 62:293–311 (1987).
Picard et al., Can. J. Microbiol., 26:985–991 (1980).

Quaife, “A New Weapon Against Swine Dysentery', Swine
Practitioner at pages 10-11, Oct., 1990.
Ramanathan et al. “Identification and Partial Characteriza

tion of a Group of Weakly f-hemolytic Intestinal Spiro
chetes of Swine Distinct from Serpulina innocens Isolate,”

Vet. Microbiol, 37:53–64 (1993).
Rychlik et al., Nucleic Acid Res., 17:8543–8551 (1989).
Saiki et al., Science, 239:487 (1988).

Schafer et al., “Rapid Identification of Serpulina hyodysen
teriae By Polymerase Chain Reaction Amplification of a
DNA Sequence Unique to Serpulina hyodysenteriae, 32nd
North Central Conference Veterinary Laboratory Diagnos

ticians, Madison, WI, Jun. 6-9 (1993).
Schlink et al., Can. J. Comp. Med., 47:320 (1983).

Sellwood et al., “Outer Envelope and Axial Filament
Polypeptides of T. hyodysenteriae, Characterization and
Molecular Cloning.” Proc. Inter. Pig. Vet. Soc., at page 119

(1990).

Sellwood, Proc. 12th Cong. Int. Pig Vet. Soc., The Hague,

The Netherlands, at page 264 (1992).
Smith et al., Vet. Microbiol., 24:29-41 (1990).

Sommer et al., “Minimal Homology Requirements for PCR

Primers,” Nucleic Acids Res., 17(16):6749 (1989).
Songer et al., Am. J. Vet. Res., 39:913–916 (1978).

Sotiropoulos et al., J. Clin. Microbiol, 31:1746–1752

(1993).

Katz et al., “Colorimetric Diagnosis of Prolonged Blue
tongue Viremia in Sheep, Using an Enzyme-Linked Oligo
nucleotide Sorbent Assay of Amplified Viral Nucleic Acids.”

Sotiropoulos et al., J. Clin. Microbiol, 32:1397-1401

Am. J. Vet. Res., 54:2021–2026. (1993).
Kent et al., J. Gen. Micro, 135:1625 (1989).
Kinyon et al., Infect. Immun., 15:638-646 (1977).
Kinyon et al., Int. J. Syst. Bact., 29:102-109 (1979).
Kohler et al., Nature, 256:496–97 (1975).
Koopman et al., “Cloning and DNA Sequence Analysis of a
Serpulina (Treponema) hyodysenteriae Gene Encoding a

Stanton et al., “Reclassification of Treponema hyodysente
riae and Treponema innocenS in a New Genus, Serpulina
gen. nov., as Serpula hyOdysenteriae comb. nov. and Serpula
innocens comb. nov.” Int. J. Syst. Bacteriol., 41:50-58

Periplasmic Flagellar Sheath Protein.” Infect. Imm.,

60:2920–2925 (1992).
Kunkle et al., J. Clin. Microbiol., 24:669–671 (1986).
Kunkle et al., J. Clin. Microbiol. 26:2357–2360 (1988).

(1994).
Southern et al., J. Mol. Biol, 98:503–517 (1975).
Stanton et al., Vet. Microbiol., 18:177-190 (1988).

(1991).

Stanton et al., “Proposal to Change the Genus Designation
Serpula to Serpulina gen. nov. Containing the Species Ser
pulina hyOdysenteriae comb. nov. and Serpulina innocenS

comb. nov.” Int. J. Syst. Bacteriol, 42:189-190 (1992).
“Swine Dysentery Products” in Annual Guide to Herd

Kunkle et al., “Recombinant DNA Technology in Control
ling Swine Dysentery,” 1992 Nebraska Swine Report at

Health. Pork 94 at pages 54–55 (1994).

pages 3–4 (1992).
Lee et al., Vet. Microbiol., 34:35–46 (1993).
Lemcke et al., Vet. Rec., 14:548–551 (1979).
Lemcke et al., J. Hygiene, 86:173 (1981).
Li et al., J. Clin. Microbiol., 29:2794–2797 (1991).

ter Huurne, “Swine Dysentery Pathogenesis and Vaccine
Development,” Ph.D. Dissertation, University of Ulbrecht,

Taylor et al., Proc. 12th Congr: Int. Pig Vet. Soc., The Hague,

The Netherlands, at page 280 (1992).
Nov. 1993.

Thomas et al., J. Med. Microbiol., 37:214–220 (1992).

5,869,630
Page 3

Torp et al., Proc. 12th Cong. Int. Pig Vet. Soc., The Hague,
The Netherlands, at page 270 (1992).
Wannemuehler et al., Infec. Immun., 56:3032-3039 (1988).

Welsh et al., “Fingerprinting Genomes Using POR with
Arbitrary Primers”, Nucleic Acids Res., 18:7213–7218

(1990).

Williams et al., Nucleic Acid. Res., 18:6531 (1990).

Wright et al., J. Clin. Micro, 27:411-416 (1989).
Matthews, et al., “Analytical Strategies for the Use of DNA

Probes", Anal Biochem. 169:1–25, (1989).

U.S. Patent

5,869,630

Sheet 1 of 6

Feb. 9, 1999

CGCCCACTCC CAAGCTTTAC CAGTTGAGGG CGACTATTAT TCTGATAAAA AAATGTTAAG
AAGATTAGAC CCTTTTATTA ATTTTGGAAT ATATGCCGCT CATCATGCAT

TTAAGCAGGC

TGGTAAGAA CCGAAAACAG GCTTTGATCC TTTAAGAGCC GGTTGTGTTC
TTGGTAGCGG
TATTGGCGCT ATGACTACTC TTITATCTAA CCATCAAGTT TTACTTAATG ACGGACCTGG
CAGAGTATCA CCITTCTTTg TACCTATGCA AATAATCAAT ATGACACCTG

GTTTAATATC
TATGGAAAT GGTATGAACG GACCTAACTA CAGTACAGTT ACTGCATGTG CTTCTTCAAA
CCACTCTATA GGTTTAGGTT ATAAACATAT TAAAGATAAT GAAGCTGATA TT ATG

6O

12 O
8O

24 O
3OO
36 O

Met
1.

GTA G. GGA GGT TCT GAA GCT ACT ATA AAT CCT CTT ACT
GCT GGT
Val Val Gly Gly Ser Glu Ala Thr Ile ASn Pro Leu Thir ATA
Ile Ala Gly
O

TTo

AAT GCT AGA GCT TTA TCT ACT AGA
Arg Ala elu Ser Thr Arg
2O
25

Phe

r. ASn Ala

463

S

GAT GAT CCT GCT AAA

ASn Asp Asp Pro Ala Lys

511

3O

AGA CCT TTT GAT
GGA AGA GAC GGA CTT GCT ATA GCC AGA
Arg Pro Phe Asp Lys Gly Arg Asp Gly Leu Ala
Ile Ala Arg
4. O

45

ATA

AAT GGC TAT GAT GTA

Ile Lys Asn

Gly Tyr ASp Val Lys
SS

AGA GTT

ATA TAT AC ACA GGA AAT
le Tyr Ile Thir Gly ASn
6O
65

GAT ACC TAC TCT AAC TTT AAT ATA TTA
Ser ASn Phe Asn Ile Lell
75
8O

Arg Val Asn Lys ASp Thr Tyr
7O

Lys

AAT ATA GAT ATT AAT TAT ITA GGA AGC GAA GAA
GAT GCC ATA
ASn Ile ASp Ilie Asn Tyr Teu Gly Ser Glu Glu
Asp
Ala Ile
85
9O
95
TCA
Ser

GCA GAA AAT ATA GAA AGA
TCA ATA GTA TTA GAT TCA TA
Ala Glu ASn Ile Glu Arg Lys Ser Ile Val Leli Asp Ser
Tuell
OO
O5

TT

655

703

751.

11 O

CI ACA GGC GGA AAC AGA CCT TTA GAA GGA ATA CAA
Asn Arg Pro fuelu Glu Gly Ile Gln

Phe Gly Thr Gly Gly
C

6 OT

l2O

GCT CTT
Leu

Lys Ala

799

125

ATA GAT AGT TTG AAT
TTA GAT GT CTT AGA
GCA ATA GAT ATA
Ile ASp Ser Lell ASn Lys Telu Asp Val Leu Arg ATA
Ile
Ala
Ile Asp Ile
3C
135
14 O
45

F.G. 1A

847
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CT TCA. GGA TTA GCT TCA AAA ATA AAT GAT AAT GAC AAT GTA TAT ACT

895

Pro Ser Gly Leu Ala Ser Lys Ile Asn Asp Asn. Asp Asin Val Tyr Thr
15 O

15 O

16 O

TGT. T.T. AAA GCA CAT GAA ACA. TAT ACT ATA TGC TTC GCT AAA GAT ATA

943

Cys Phe Lys Ala His Glu Thr Tyr Thr Ile Cys Phe Ala Lys Asp Ile
1.65

17 O

75

TTC TTT TTA. TAC AGA ACA AGA GAA TAT ATA GGA AAA TTA TTC ATA ATA

99.

Phe Phie Leu Tyr Arg Thr Arg Glu Tyr Ile Gly Lys Leu Phe Ile Ile
8O

85

19 O

AAA TCA, ATA TTC CCA GAT GAA. ATA TTA. GAT AAT TGG GGA TAT AAA GCT

O 39

lys Se: Ile Phe Pro Asp Glu Ile Leu Asp Asn Trp Gly Tyr Lys Ala
19

2OO

2O5

AAA CiT ATA GAT TAT AAT GAA AAA ATA AAT ATA AAT AGA AAC

CT CTA

O87

ys i.eu ille Asp Tyr ASn Glu Lys Ile ASn Ile ASn Arg Asn Ser Lieu
C

215

220

225

AC AGC AAA AGA GAA CAA. GGA ATG CTT GCT ATA GTA GCA GGA AGT GAT

1135

Tyr Ser Lys Arg Glu Glin Gly Met Leu Ala Ile Val Ala Gly Ser Asp
23 O

235

240

AAT TAT ATA GGG GCT GCT GTT CTA GCT GTA AAT GCT GCT TAT AGA TTG

183

Asn Tyr Ile Gly Ala Ala Val Lieu Ala Val Asn Ala Ala Tyr Arg Leu
245

25 O

255

GGT GTA. GGA TAC ATA AGA TTA. TAT GTA CCT AAA GGC ATA ATA AAA AAT

1231.

Gly Val Gly Tyr Ile Arg Lieu Tyr Val Pro Lys Gly Ile Ile Lys Asn
26 O

265

27 O

ATA AGA GAT GCC ATA ATG CCT TCT ATG CCT GAA ATT GTT ATT ATA GGA

279

ille Arg Asp Ala Ile Met Pro Ser Met Pro Glu Ile Val Ile Ile Gly
275

28 O

GTT GGA GAA GAA AAT CAA AAA

28S

TC TTC ACA GAA AAT GAC ATT GAA ATA

327

Val Gly Glu Glu Asn Glin Lys Phe Phe Thr Glu Asn Asp Ile Glu Ile
29 O

295

3OO

3O5

GTA AAT GAT ATI AAT AAA AGC GAT GCT TGT ATA ATA GOGT

CT GGT ATA

375

Val Asn Asp Ile Asn Lys Ser Asp Ala Cys Ile Ile Gly Ser Gly Ile
31 O

35

GGC AGA GAT TTG TCT ACA GAA ATT IIT GTA AA

32O

ACT ATA ITA AAG CAA

1423

Gly Arg Asp Leu Ser Thr Glu Ile Phe Val Asn Thr Ile Leu Lys Glin
3 25

33 O

335

ATA AAT ATA CCT ACT GTT ATT GAT GCT GAT GCT TTA. TAT TTA ATG TTT

Ile Asn Ile Pro Thr Vall. Ile Asp Ala Asp Ala Leu Tyr Leu Met Phe
34 O

343

35 O

FIG. 1B

471

U.S. Patent

Feb. 9, 1999

Sheet 3 of 6

5,869,630

GAA AGC ACT CTT AAT GAA CTT AAT AAT AAT TTT ATA ATC ACT CCT CAT

19

Glu Ser Thr Lieu Asn Glu Lieu. Asn. Asn Asn Phe Ile Ile Thr Pro His
35 E.

36 O

365

ATA TAT GAA TTT GAA. AAA CTT ACA CAG ATA AAT CAT ATA GAG GTT TTA

S 67

Ile Tyr Glu Phe Glu Lys Leu Thr Glin Ile Asn His Ilie Glu Val Leu
37 C.

375

38 O

385

GAA AAT CCT TAT CAG GCA TTA TTA ATA TAC AGA GAA AAA ACT AAT GCC

1615

Glu Asr, Pro Tyr Glin Ala Leu Leu Ilie Tyr Arg Glu Lys Thr Asn Ala
39 O.

395

4 OO

TCA ATA GTA TTA AAA GAT GCT GTA AGT TTC CTA ATG CAT GAA AAT GAT

Ser

1663

le Val Leu Lys Asp Ala Val Ser Phe Leu Met His Glu Asn Asp
4 O5

410

45

ATA TA, ATA AAT TAT AAC CCT AGA GAA TCT ATG GGG AAA GCA GGT ATG

1711

Ile Tyr Ile Asn Tyr Asn Pro Arg Glu Ser Met Gly Lys Ala Gly Met
420

GGT GA

425

43 O

GTT TTT GCT GGA TTT ATA GGT GCT TTG CTC GCT AGA AAA CTA

17 S 9

Gy Asp Val Phe Ala Gly Phe Ilie Gly Ala Leu Lleu Ala Arg Llys Lieu
43

440

445

AAT ATA TTA GAT GCT TCA AAA CTA GCA TTG ATA ATA CAG GCT AAA TCT

18 O 7

Asn Ile Leu Asp Ala Ser Lys Leu Ala Leu Ile Ile Glin Ala Lys Ser
4 SO

4S5

46 O

4 65

TTT AAT ATA TTA TCA AAA AAA TTC GGA AAT GAT TAT ATT CAG CCT AAA

855

Phe Asn. Ile Leu Ser Lys Lys Phe Gly Asn Asp Tyr Ilie Glin Pro Lys
47 O

475

A 8O

GAT TTG GCA AAT ATT TCA. TAT AAA ATA CTA AAA GGA TAT AAA TTT GCC

19 O3

Asp Leu Ala Asn. Ile Ser Tyr Lys Ile Leu Lys Gly Tyr Lys Phe Ala
485

49 O

4.95

TAGAGAAGTT TACGACCCTA AACAAAAAGA ATTAGAATTC TACGCTAAAA GAGAGGTAAA

1963

(CCCCCTGCT CCTAAAAGAG. AGGTA AGCAT ATTTGCTAGA AGATGGTTTA TGTTTTTATA

2023

CGGAACTTC CTCACATTAG TTGTAATTGG TATGCTTTTA TATAAAAAAG GATTCTTTAA

2O83

TAATATACCA TTATTTGAAG CTTTAAAGCC TAAAACAGAT GTTATAGTAA AAATTAATAA

243

TGCTGAATTC GTTAATGATG CAGTAATTAC AACTATAGAA CTCGAAAATT CAAATTATAC

2203

TAATTCTCAA AGTATAGAAA CACTAAGAAG TTATTTTTCA TTGTACAAAA, ATAGAAAATT

2263

AATATTTACA GGCAATCGTT CTTTTAATAA TATAAGATTC CCAGTAGGTC AGAGAATAGG

232 3

ATCAATTT

2332
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1
NUCLEOTIDE SEQUENCES FOR
DETECTION OF SERPULINA
HYODYSENTERIAE

This is a divisional of copending application Ser. No.

5

08/252,492 filed on Jun. 1, 1994.
STATEMENT REGARDING FEDERALLY
SPONSORED RESEARCH

The invention described herein was made with the assis

tance of funds provided by the U.S. Department of
Agriculture/CSRS, Animal Health Project No. Neb. 14-048,
Immunobiology of Enteric Diseases of Swine and Cattle;
U.S. Department of Agriculture, Regional Research Project
NC-62, Prevention of Enteric Diseases of Swine; U.S.

15

infection of the animal at the time of collection. Kunkle and

Department of Agriculture/NC-IPM, No. Neb. 14-062, Inte
grated Management Practices for Control of Swine Dysen
tery and Salmonellosis. The Government has certain rights

Kinyon reported that the numbers of S. hyodysenteriae in
porcine colonic contents at the onset of Swine dysentery

ranged between 2x10° and 2x10' CFU/g when cultured

in the invention.

using the selective BJ medium. Kunkle et al., J. Clin.

Microbiol., 26:2357–2360 (1988). In contrast, subclinically

BACKGROUND OF THE INVENTION

Swine dysentery is a highly contagious disease of grow
ing and finishing Swine which has a significant economic
impact on the United States Swine industry. Although the
causative agent has been known for nearly 20 years, no

25

effective measures, other than medication of animals and

Sanitation of premises, are available to prevent the occur
rence of the disease or reduce its Severity once introduced
into a susceptible herd. Recently published data from Iowa
State University indicated a projected Statewide cost for
prevention and control of Swine dysentery of approximately
S2.4 million per month. Since the Iowa Swine population
represents one-fourth of the nation's industry, the annual
losses due to Swine dysentery for the United States may
represent as much as S115.2 million. Owen, Iowa State J.

35

Res., 62:293–311 (1987).

Serpulina hyOdysenteriae is the primary etiologic agent of
Swine dysentery. Harris and Lysons, Diseases of Swine, 7th

ed., Iowa State University Press (Ames, IA), at pp. 599–616
(1992); and Stanton et al., Int. J. Syst. Bacteriol, 41:50-58
(1991). Nine serotypes of S. hyodysenteriae have been

based on herd history, clinical Signs, observation of charac
teristic intestinal lesions, and isolation of S. hyodysenteriae
from feces or intestine using Selective agar medium incu
bated anaerobically for 2 to 4 dayS. Chengappa et al., Report
of the Committee On Swine Dysentery, American ASSociation
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supra; Burrows et al., Vet. Rec., 108:187-189 (1981); Kin
yon et al., Infect. Immun., 15:638-646 (1977); Lymbery et
al., Vet. Microbiol., 22:89-99 (1990); Picard et al., Can. J.
Microbiol., 26:985–991 (1980); Ramanathan et al., Vet.
Microbiol, 37:53-64 (1993); and Torp and Thorensen, Proc.
12th Congr. Int. Pig Vet. Soc., The Hague, The Netherlands,

at page 270. (1992). In addition, the biochemical tests
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Kinyon and Joens, (1979). As a result, a definitive diagnosis

Harris, Am. J. Vet. Res., 39:913–916 (1978); and Fisher and

serum (Lemcke and Burrows, Vet. Rec., 104:548–551
(1979)) and rapid slide agglutination (Burrows and Lemcke,
Vet. Rec., 108:187-189 (1981)). In addition to problems of
to grow. Lysons, Vet. Rec., 129:314-315 (1991). Although
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f3-hemolytic intestinal spirochetes (WBHIS) are present in

the Swine population.
An important aspect of Swine dysentery is the occurrence
of prolonged Shedding of S. hyodysenteriae in the feces of
Some animals following recovery from diarrhea. Songer and

require growth of the organism for 2 to 4 dayS.
Other methods of differentiating S. hyodysenteriae from
WBHIS include growth inhibition by discs soaked in anti

non-specific clumping of Spirochetes in the Saline control in
the slide agglutination test, these tests require large numbers
of pure culture of Spirochetes which can take up to 3 weeks

innocenS, a common inhabitant of the colon of Swine.

of Swine dysentery can be very challenging particularly
when the disease occurs on premises where weakly

et al., J. Vet. Diag. Invest., 3:211-214 (1991); Belanger et al.,
J. Clin. Microbiol., 29:1727–1729 (1991); Hunter et al., Vet.
Rec., 104:383–384 (1979); and Smith et al., Vet. Microbiol.,
24:29-41 (1990). Although these biochemical characteris
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of Veterinary Laboratory Diagnosticians, Inc. (Columbia,
Mo.) (1989). Laboratory confirmation of S. hyodysenteriae

by culture is based upon colony morphology, pattern and
intensity of hemolysis, and other growth characteristics, all
of which are very similar for the non-pathogenic Serpulina

affected animals may shed recoverable numbers of Spiro
chetes only sporadically and in much lower numbers than
animals with clinical Swine dysentery often resulting in false
negative culture results. Field cases of Swine dysentery also
may contain drug residues that adversely affect recovery of
viable S. hyodysenteriae by culture.
Identification of S. hyodysenteriae by culture is highly
Subjective and can lead to false results, particularly when
results of cultures are interpreted by inexperienced labora
tory workers. For this reason, Several biochemical tests have
been proposed for rapid differentiation of enteropathogenic
and non-pathogenic intestinal Spirochetes of Swine. Achacha

tics are highly conserved among field isolates of S.
hyodysenteriae, WBHIS have been shown to yield highly
variable results making a conclusive identification of S.
hyOdysenteriae based on biochemical tests alone practically
impossible. Achacha et al, cited Supra; Belanger et al., cited

recognized Worldwide, with Serotypes 1 and 2 being the
most prevalent in the United States. Baum and Joens, Infect.

Immun., 25:792–796 (1979); Mapother and Joens, J. Clin.
Micro., 22:161-164 (1985); and Liet al., J. Clin. Microbiol.,
29:2794–2797 (1991). The diagnosis of swine dysentery is

2
Olander, Am. J. Vet. Res., 46:450-455 (1981). Asymptom
atic carrier-Shedder Swine are important reservoirs for main
tenance of S. hyodysenteriae on infected premises and
transmission of the organism to uninfected premises. The
Solution to Swine dysentery prevention lies in being able to
quickly and accurately identify carrier-Shedder Swine and
avoid their entry into uninfected herds. However, identifi
cation of asymptomatic carrier-Shedders of S.
hyodysenteriae, is difficult due to the detection limits of
currently available laboratory isolation procedures.
Direct culture of diagnostic Specimens is the only method
available for laboratory identification of S. hyodysenteriae.
However, it is well known that the sensitivity of the direct
culture method depends upon the number of organisms
present in the Sample, which in turn depends on the Stage of

65

pre-absorption of reference polyclonal antisera with WBHIS
increases the Specificity of the Serological tests, occasional
S. hyodysenteriae isolates continue to be falsely classified as
non-pathogenic in these tests. An alternative method using
microscopic agglutination under phase contrast or dark field
microScopy was recently proposed. However, Some isolates
of S. hyodysenteriae gave weaker reactions in that assay than

with the Slide agglutination test (LySons, cited Supra).
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monoclonal antibody reactive with the peptide. The inven
tion also provides for a method of immunizing animals and
vaccine preparations for protecting animals against disease
caused by S. hyodysenteriae. The methods and compositions
of the invention are useful to identify at least one Serotype
of S. hyodysenteriae, to diagnose S. hyodysenteriae

3
Mouse monoclonal antibodies capable of differentiating
S. hyodysenteriae from porcine WBHIS have also been
proposed as potential diagnostic reagents. Sellwood et al.,
Proc. 12th Congr: Int. Pig Vet. Soc., The Hague, The

Netherlands, at page 264 (1992); and Thomas and Sellwood,
J. Med. Microbiol, 37:214–220 (1992). However, other

infection, to detect carrier-Shedder animals, to monitor effi

Studies, indicate that Spirochetes other than S. hyodysente
riae can express antigenic determinants recognized by these
reagents and cause false positive results. Taylor et al., PrOC.
12th Conqr. Int. Pig Vet. Soc., The Hague, The Netherlands,

at page 280 (1992). The fact that no Serological reagents are

available commercially also limits the applicability of Sero
logical techniques to routine diagnosis of Swine dysentery.
Certain genes encoding S. hyodysenteriae antigens and
capable of eliciting protection against infection in mice have
been cloned and expressed in Escherichia coli using a phage
expression System. Boyden et al., Infect. Immun.,
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57:3808-3815 (1989). However, none of these reagents

have been examined for potential application as diagnostic
tools. One of the most recent diagnostic applications of
recombinant DNA technology to Swine dysentery control
used oligodeoxynucleotide probes to 16S rRNA of S. hyo
dysenteriae. Jensen et al., J. Clin. Microbiol., 28:2717-2721

ably has a nucleotide sequence as shown in FIG. 1 (SEQ ID
NO:1). The DNA amplification products specific for S.
hyodysenteriae can be detected by (a) extracting DNA from
a biological Sample; (b) amplifying a target Sequence of the
extracted DNA to provide DNA amplification products

(1990). However, the sensitivity of this probe method for
detection of Spirochetes in feces was equivalent to routine

25

bacteriological culture (10 organisms/g of feces), and fur
ther studies question the specificity of the 16S rRNA probe

to S. hyodysenteriae (Torp and Thoresen, cited Supra). Dot

5'-GGTACAGGCGGAAACAGACCTT (SEQ ID NO:3), or
negative-sense 5'-TCCTATTCTCTGACCTACTG (SEQ ID

NO:4), or complements thereof or mixtures thereof.
35

only slightly better than culture (10' organisms/g of feces).

the environment in contact with infected animals.
SUMMARY OF THE INVENTION

These and other objects are achieved by the present
invention which is directed to a method for detecting the
presence of at least one Serotype of Serpulina hyOdysente
riae in a biological Sample, an oligonucleotide primer, and
a S. hyodysenteriae-Specific oligonucleotide probe useful in

40
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The amplification products can be detected, for example,
by dot blot or Southern blot analysis including by reacting
the DNA amplification products with a labeled oligonucle
otide probe that can hybridize to the about 2.3 kb HindIII
DNA fragment of S. hyodysenteriae B204 serotype 2 shown
in FIG.1. Prior to detection, the DNA amplification products
can optionally be separated by electrophoresis.
Alternatively, the PCR products can be detected by immo
bilization to a bead or a multiwell plate by a probe or primer
labeled with biotin, followed by hybridization with a detect
ably labeled probe. The oligonucleotide probe preferably
hybridizes to all or a portion of a 2.3 kb HindIII DNA
fragment of S. hyodysenteriae B204 serotype 2 having the

nucleotide sequence shown in FIG. 1 (SEQ ID NO:1). The
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detection of amplified products preferably allows for the
detection of all serotypes of S. hyodysenteriae at low levels

of bacteria in the sample (i.e., about 1 to 10 microorganisms/
0.1 gm sample).
The invention provides an isolated HindIII DNA fragment
of about 2.3-kb that is derived from a partial digest of
chromosomal DNA of S. hyodysenteriae B204 serotype 2
with HindIII, which encodes for an about 56 kDa polypep
tide. The DNA fragment preferably has the nucleotide

sequence shown in FIG. 1 (SEQ ID NO:1).
60

that method, and an article of manufacture (i.e., kit) con

taining the primers and/or probe. Also provided are an about
2.3-kb DNA fragment derived from chromosomal DNA of S.
hyodysenteriae B204 serotype 2 that encodes for an about 56
kDa polypeptide, a recombinant expression vector contain
ing the DNA fragment, the about 56 kDa polypeptide and a

the presence of S. hyodysenteriae by detecting the presence
of the DNA amplification products. Preferably, the amplifi
cation of the DNA sequence is by polymerase chain reaction

merase and at least one oligonucleotide primer. The primers
preferably have a Sequence of positive-Sense

50:286-289 (1991); Sotiropoulos et al., J. Clin. Microbiol.,
31:1746-1752 (1993); and Sotiropoulos et al., J. Clin.
Microbiol, 32:1397-1401 (1994). Although the sensitivity

These tests are labor intensive, require Specialized
equipment, and have turn-around times that are incompat
ible with routine laboratory diagnosis.
A Solution to prevention of disease caused by S. hyodys
enteriae lies in being able to quickly and accurately identify
carrier-Shedder animals and avoid their entry into uninfected
herds. Therefore, there is a need to develop a method and
reagents for detecting S. hyodysenteriae in low numbers
Specifically, rapidly and directly from diagnostic and envi
ronmental Samples. There is also a need to develop a
Sensitive and Specific method for rapid detection of S.
hyOdysenteriae in a biological Sample to diagnose and
monitor infection in acutely- or Subclinically-infected ani
mals before, during and after treatment and in their envi
ronment. There is also a need to develop a method for rapid
detection of S. hyodysenteriae for monitoring disinfection of

carrying a selected target DNA sequence; and (c) detecting
(PCR) by amplifying the gene sequence with DNA poly

blot hybridization with whole-chromosomal probes and
DNA probes for identification of S. hyodysenteriae have
been reported. Combs and Hampson, Res. Vet. Sci.,
of the whole-chromosomal probes was not reported, colony
dot blot hybridization with DNA probes was shown to be

cacy of treatment for disease caused by S. hyodysenteriae, to
monitor disinfection of fomites, and to protect animals from
infection with S. hyodysenteriae.
According to the invention, a biological Sample of an
animal Such as feces, intestinal contents, mucosal Scrapings,
rectal Swabs, and environmental Samples among others, is
tested for the presence of at least one Serotype of S.
hyOdysenteriae by measuring the presence or absence of
DNA amplification products from a primer that hybridizes to
a 2.3 kb HindIII restriction fragment of S. hyodysenteriae
B204 serotype 2. The 2.3 kb HindIII restriction fragment
was obtained from a partial digest with HindIII and prefer

The DNA restriction fragment may be incorporated into
an expression vector. The expression vectors include the
restriction fragment operably linked to transcriptional and
translational control regions in the vector. The expression
vectors are useful to form transformed cells. The trans
formed cells can be used to Screen monoclonal antibodies
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Specific for S. hyodysenteriae to produce a 56 kDa polypep
tide of S. hyodysenteriae, to prepare mutant Sequences of the
2.3 kb HindIII restriction fragments, and as an intermediate

5,869,630
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S
to prepare the 2.3 kb HindIII restriction fragment for DNA
sequencing. A puC18 plasmid carrying the 2.3 kb HindIII
restriction fragment from S. hyodysenteriae B204 and des
ignated pRED3C6, deposited with the American Type Cul
ture Collection, Rockville, Md., has been given Accession

shedder animals are not formed. The method involves moni

No. 75826.

Also provided are oligonucleotide primers that hybridize
to all or a portion of a DNA sequence of the 2.3 kb HindIII

fragment of S. hyodysenteriae B204 serotype 2 (SEQ ID
NO:1). The DNA sequence of a oligonucleotide primer is
preferably

positive - Sense

5'-GGTACAGGCGGAAACAGACCTT (SEQ ID NO:3)
and negative-sense 5'-TCCTATTCTCTGACCTACTG

(SEQ ID NO:4), or complements thereof or mixtures

thereof. The primers can be complementary to the 3' or 5'
end of the target Sequences. The primers can also have
mismatches with the target Sequence or be degenerate.
The target DNA sequence is also useful in providing an
oligonucleotide probe for detecting a target Sequence of at
least one Serotype of S. hyodysenteriae. The probe is pref
erably hybridizable with a DNA sequence located on the 2.3
kb HindIII fragment of the chromosomal DNA of S.
hyodysenteriae, preferably a 1.55 kb DNA sequence within
the 2.3 kb fragment. The DNA sequence of the oligonucle
otide probe is preferably hybridizable to all or a portion of
the 2.3 kb HindIII fragment of S. hyodysenteriae B204, as
shown in FIG. 1, and can distinguish S. hyodysenteriae from
other microorganisms and cells in a biological Sample.
The about 56 kDa polypeptide encoded by the about 2.3
kb DNA fragment is useful in eliciting antibodies that are
specifically reactive with S. hyodysenteriae. The 56 kDa
polypeptide and nucleotide Sequence encoding the polypep
tide may also be useful in a vaccine preparation to provide
a protective effect for an infection caused by S. hyodysen
teriae. The invention further provides an in vitro assay for
detecting S. hyodysenteriae-specific antibodies in a Sample.
In that method, a Sample to be tested is contacted with a
composition containing the about 56 kDa polypeptide,
which is preferably labelled, to form a conjugate which is
then detected.
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BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the nucleotide sequence of the recombinant
2.3-kb HindIII DNA fragment from Serpulina hyodysente
25

FIG. 2 is an image of a Southern blot hybridization using

C-'PdCTP labelled 2.3 kb fragment of clone pRED3C6 to

35

purified chromosomal DNA. Purified chromosomal DNA
was digested with HindIII, electrophoresed on a 0.8% aga
rose gel, and transferred to a nylon membrane. Lanes 1 to 8,
Serpulina hyodysenteriae isolate B78, B234, B204, B169,
Al, B8044, B6933, and AcK300/8, respectively; lanes 9 to
12, WBHIS B256, B359, B1555a, and 4/71, respectively;
lane 13, Treponema Succinifaciens.
FIG. 3 is an image of an ethidium bromide Stained agarose
gel and Southern blot hybridization of PCR using purified
chromosomal DNA obtained from reference isolates of S.

40

hyodysenteriae serotypes 1 through 9. The amplified prod
ucts were electrophoresed on a 0.8% agarose gel and Stained
with ethidium bromide. The insert at the bottom of the

photograph shows hybridization of transferred DNA from
the same gel with an internal S. hyodysenteriae-specific
45

oligonucleotide probe 5'-end labelled with Y- PATP.

Lanes: 1, molecular weight standard (1-kb DNA ladder;
GIBCO-BRL); 2, B78; 3, B204; 4, B169; 5, A1; 6, B8044;
7, B6933; 8, AcK300/8; 9, FM-88-90; 10, FMV 89-3323.

FIG. 4 is an image of an ethidium bromide Stained agarose

50
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gel (panel A) and Southern blot hybridization (panel B) of
PCR using purified DNA obtained from porcine feces inocu
lated with serial ten fold dilutions of Serpulina hyodysen
teriae isolate B204 cells. FIG. 4A shows the amplified
products electrophoresed on a 0.8% agarose gel and Stained
with ethidium bromide. FIG. 4B shows hybridization of
transferred DNA from the same gel with an internal S.
hyodysenteriae-Specific oligonucleotide probe 5'-end

labelled with Y--PATP. Lanes: 1, molecular weight stan
dard (1-kb DNA ladder; GIBCO-BRL); lanes 2 to 9, feces
60

containing 10, 10, 10, 10, 10", 10, 10, 10° S.
hyOdysenteriae cells/0.1 g, respectively.

The kits and methods of the invention can be used to

identify at least one Serotype of S. hyodysenteriae to diag
nose S. hyodysenteriae infection, detect carrier-Shedder
animals, monitor the efficacy of treatment for diseases
caused by S. hyodysenteriae, or monitor disinfection of the
environment. A method for monitoring the efficacy of treat
ment is useful to ensure that Subclinically infected or carrier

riae (SEQ ID NO: 1) which indicates a single open reading

frame encoding a protein with a predicted molecular weight

of approximately 56 kDa (SEQ ID NO:2).

An article of manufacture (i.e., kit) is also provided for

use in the detection of at least one Serotype of S. hyodyS
enteriae in a biological Sample. The kit is composed of one
or more reagents contained within a packaging material, the
reagents useful for detection of the Spirochete including at
least one oligonucleotide primer that hybridizes to a DNA
sequence of the 2.3 kb fragment of S. hyodysenteriae B204
as shown in FIG. 1, and/or an oligonucleotide probe which
is hybridizable to all or a portion of a DNA gene Sequence
included in the 2.3 kb gene fragment, preferably an about
1.55 kb gene fragment. The kit may optionally include
instruction means with information regarding the use of the
reagent and/or other component of the kit Such as how to
conduct an assay, and the like. The instruction means may be
a label or tag attached to the packaging, a printed package
insert, and the like. Two or more reagents and/or other
components may be combined together to form the kit,
preferably packaged together within containing means Such
as a box or plastic bag, and the like.

toring the presence of S. hyodysenteriae throughout the
course of treatment of the animal. The presence of S.
hyOdysenteriae in a biological Sample from the treated
animal is detected by detecting DNA amplification products
of a target Sequence of S. hyodysenteriae, wherein the target
sequence is a 2.3 kb HindIII restriction fragment of S.
hyOdysenteriae.
The invention also provides for vaccines and methods of
immunizing an animal to produce a protective immune
response against S. hyodysenteriae infection. The vaccines
include an amount of a 56 kDa polypeptide encoded on a 2.3
kb HindIII restriction fragment of S. hyodysenteriae B204
effective to induce a protective response to S. hyodysenteriae
infection. The vaccine preparations are in admixture with a
physiologically acceptable carrier and can be administered
to animals using Standard methods. The vaccines and meth
ods of the invention are useful to prevent the adverse effects
of disease caused by S. hyodysenteriae.

DETAILED DESCRIPTION OF THE
INVENTION
65

The invention provides for methods, kits and composi
tions useful for diagnosis and monitoring of infection of
animals with at least one Serotype of S. hyodysenteriae. The
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compositions include probes and primers that can hybridize
to a target Sequence of at least one Serotype of S. hyOdyS
enteriae. The probes and primers can preferably hybridize to
all Serotypes of S. hyodysenteriae and not other closely
related microorganisms. The target Sequence is preferably
about a 2.3 kb fragment of S. hyodysenteriae chromosomal
DNA having the nucleotide sequence shown in FIG. 1 (SEQ
ID NO:1). The primers and probes can be used in methods
and kits for detecting S. hyodysenteriae in a biological
Sample, preferably by detecting amplification products using
primers that hybridize to the target Sequence.
The invention also provides a 56 kDa polypeptide
encoded by a 2.3 kb HindIII restriction fragment of S.
hyodysenteriae B204, as shown in FIG. 1. The polypeptide
and nucleotide Sequences are useful to elicit antibodies and

8
of Nebraska, Lincoln, Nebr) raised against cell-free Super

15

in vaccine formulations. The vaccine can be administered to

animals to induce a protective immune response against
infection with S. hyodysenteriae.
1. Primers and Probes that Hybridize to a Target Sequence
of S. hyodysenteriae
Primers and probes of the invention are useful for iden
tification of at least one Serotype of S. hyodysenteriae in a
biological Sample. The primers and probes are preferably
those that hybridize to a target Sequence of about a 2.3 kb
fragment of S. hyodysenteriae B204 having the nucleotide

25

sequence of FIG. 1 (SEQ ID NO:1). Hybridization of the

primerS and/or probes to the target Sequence preferably can
provide for identification of all serotypes of S. hyodysente
riae and distinguish S. hyodysenteriae from other cells and
closely related microorganisms. Primers can be useful in a
diagnostic assay to identify at least one Serotype of S.
hyOdysenteriae and to distinguish S. hyodysenteriae from at
least one other microorganism, and to form probes or to form
deletion mutants of the target Sequence. Probes are useful to
identify at least one Serotype of S. hyodysenteriae and/or to
distinguish S. hyodysenteriae from at least one other
microorganism, to identify amplification products of a target
Sequence, and to identify other target Sequences.
Primers and probes in accord with the invention are
Selected So that they can Specifically identify at least one
Serotype of S. hyodysenteriae, preferably all Serotypes.
Those primerS or probes that can Specifically identify S.
hyOdysenteriae are those that hybridize to a target Sequence
preferably found in all Serotypes and not found in other
closely related microorganisms. One Such target Sequence
identified in all serotypes of S. hyodysenteriae is about a 2.3
kb fragment of S. hyodysenteriae B204 shown in FIG.1. The
2.3 kb fragment was obtained by partial digestion of chro

35
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mosomal DNA with HindIII.

The target Sequence Specific for S. hyodysenteriae can be
identified from a DNA or cDNA library of S. hyodysenteriae
chromosomal DNA or mRNA, respectively. A DNA or
cDNA library can be generated by Standard methods using
a restriction enzyme such as HindIII. Suitable host cells such

50

as E. coli DH5C. and the like are transformed with the

55

library. Transformed cells can be screened by a variety of
Standard methods including by reactivity with antibodies
that react with antigens of S. hyodysenteriae.
Once a clone that reacts with the antibodies that react with

antigens of S. hyodysenteriae is identified, it can be ampli
fied and Sequenced. An example of a target Sequence is a 2.3
kb fragment having a nucleotide Sequence shown in FIG. 1

60

(SEQ ID NO 1). This sequence encodes a 56 kDa polypep

tide having a predicted amino acid Sequence as shown in

FIG. 1 (SEQ ID NO:2). Transformed cells including this
target Sequence were immunoreactive with monoclonal anti

body 10G6/G10 (available from Dr. Duhamel at University
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natant antigens of S. hyodysenteriae B204.
A target Sequence can be isolated and labeled with a
detectable label Such as a radioactive nucleotide. The target
Sequence can also serve as a probe and can be Screened for
hybridization to all serotypes of S. hyodysenteriae and for
lack of hybridization to other microorganisms Such as S.
innocens, WBHIS strains, Treponema spp., E. coli, Salmo
nella spp., Campylobacter spp., Bacteriodis vulgatus, Spi
rocheta aurantia, Borrellia burgdorferi, and Leptospiraceae.
Hybridization conditions are preferably low Stringency con
ditions. The target Sequence, as well as probes and primers
derived from the target Sequence, can be used to confirm the
identity of a pure culture of S. hyodysenteriae isolated by
conventional microbiological methods or isolated by immu
noaffinity methods, to distinguish at least one Serotype of S.
hyOdysenteriae from other cells in a mixed biological
Sample including other microorganisms and eukaryotic
cells. Preferably the probe derived from a target Sequence
can hybridize to all Serotypes of S. hyodysenteriae and not
to closely related S. innocens, WBHIS strains, Treponema
spp. Once a target Sequence is identified, Screened for
Specificity for at least one Serotype to S. hyodysenteriae and
Sequenced, it can be used to design primerS and/or probes.
Once the Sequence of a target Sequence from one Serotype
of S. hyodysenteriae is known, primers and probes that
hybridize to the known target Sequence can be used to
identify other closely related target Sequence from other
Serotypes that will hybridize to the same primers and/or
probes. For example, other target Sequences from other
serotypes of S. hyodysenteriae can have some DNA
sequence differences from the 2.3 kb HindIII restriction
fragment from B204 serotype 2, shown in FIG. 1, and still
be able to hybridize to primers and probes that hybridize to
the 2.3 kb sequence as shown in FIG. 1 under low, medium
or high Stringency conditions. These other target Sequences,
once identified, can be sequenced and used to provide a
template for design of primers and/or probes. Once Selected,
these target Sequences are further preferably Screened for the
ability to hybridize to Sequences in all Serotypes of S.
hyOdysenteriae and not to related microorganisms. Such as S.
innocens, Treponema spp., and WBHIS spp., and the like.
At least one primer is designed to be useful to amplify the
target DNA sequence preferably using Standard or hot start
polymerase chain reaction. A primer can preferably be about
16 to 30 nucleotides long and more preferably about 20 to
21 nucleotides long. Primers can hybridize to Sequences
flanking the desired target Sequence which is preferably all
or a portion of a 2.3 kb fragment of S. hyodysenteriae B204
having the nucleotide sequence shown in FIG. 1. Primers
can hybridize to sequences at the 5' and/or 3' ends of the
target sequence. Primers can hybridize to the DNA strand
with the coding Sequence of a target Sequence and are
designated sense primers. Primers can hybridize to the DNA
Strand that is the complement of the coding Sequence of a
target Sequence and are designated anti-Sense primerS. Prim
ers that hybridize to each strand of DNA in the same location
or to one another are known as complements of one another.
Primers can be designed to hybridize to a mRNA sequence
complementary to a target DNA sequence and are useful in
reverse transcriptase PCR.
Hybridization conditions utilized are those preferred for
polymerase chain reaction modified as required for the
degree of Sequence complementarity of the primers to the
target Sequence. Hybridization conditions for a primer of
about 16 to 30 nucleotides long having no mismatches with
the target Sequence are those described by Elders et al., J.
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Clin. Micro, 32:1497 (1994). Briefly, a PCR mixture includ
ing 4 mM MgCl, 0.2 mM dNTPs and a DNA polymerase
were mixed with the DNA extracted from the biological
sample. Initial denaturing is at 95 C. for 60 seconds
followed by 30 cycles (65° C. for 60 seconds and 72° C. for
120 seconds). The conditions selected are those described
for GenAmp 480 (Perkin-Elmer, Norwalk, Conn.).

10
about 20 to 30 nucleotides have up to 30% mismatches and
can Still hybridize to a target Sequence. Hybridization con
ditions for primers with mismatch can be determined by the
method described in Maniatis at pages 11.55 to 11.57 which
is hereby incorporated by reference or by reference to
known methods. The ability of the primer to hybridize to the
2.3 kb HindIII sequence of FIG. 1 under varying conditions
can be determined using this method. Because a target
Sequence is known, the effect of mismatches can be deter
mined by methods known to those of skill in the art.
Hybridization conditions for polymerase chain reaction
using degenerate or mismatched primers are known to those

Hybridization conditions for a primer having about 16 to
30 nucleotides and about up to 30% mismatch are modified
as described in Maniatis, Molecular Cloning. A Laboratory

Manual, Cold Spring Harbor, N.Y. (1989). The melting
temperature (T) for hybridization is decreased about 1 to

of skill in the art.

1.5 C. for each 1% of mismatch. Primers less than 20

nucleotides preferably only have about one to three mis
matches with the target Sequence located at either the 5' or
3' end of the primer. PCR methods using mismatched
primerS or degenerate primers have been described.
Primers can be designed as overlapping Sequences or a
nested Set as long as all or a portion of the target Sequence
can be amplified. Primers can include at least about 16
nucleotides Starting from the flanking Sequence immediately
adjacent to the 5' end of the target Sequence and overlapping
primers can be designed to move from the 5' end to the 3' end
of the target Sequence as shown below:
target sequence

15

In a preferred version, primer pairs are designed to flank
a desired portion of the target Sequence. A primer pair has a
first primer that hybridizes to a sense strand at the 5' end of
the target Sequence and a Second primer that hybridizes to
the anti-Sense Strand at the 3' end of the target Sequence.
Examples of the preferred primers include Sense

5'-GGTACAGGCGGAAACAGACCTT (SEQ ID NO:3);
anti-sense 5'-TCCTATTCTCTGACCTACTG (SEQ ID
NO:4). The preferred primers can hybridize to and amplify
all or a portion of a 2.3 kb HindIII restriction fragment
Sequence of S. hyodysenteriae B204 Serotype 2, as shown in
FIG. 1.
25

Once the primers are designed as described above, the
primers can be prepared by automated DNA Synthesis in
accord with Standard methods.

Likewise, primers can be designed to include about 16
nucleotides Starting from the flanking Sequence immediately
adjacent to the 3' end and then overlapping the Sequence
until the 5' end of the target Sequence. These primers can
vary in size from about 16 to 100 nucleotides. A primer that
hybridizes to a flanking region preferably hybridizes to
about 16 to 30 nucleotides immediately upstream or down
Stream from the target Sequence. These overlapping primers
provide for amplification of all or a portion of the target
Sequence preferably at least about 16 nucleotides long and
more preferably about 20 to 2,300 nucleotides long.
Primers can preferably hybridize under standard condi
tions for polymerase chain reaction to a portion of the target
nucleotide Sequence or to the flanking Sequences immedi
ately adjacent to the target Sequence and provide for ampli
fication of all or a portion of a target Sequence including
preferably a 2.3 kb HindIII partial digest restriction fragment
of S. hyodysenteriae B204. Primers preferably hybridize to
the target Sequence with no mismatches. However, primers
can have additional nucleotide Sequence at the 5' or 3' ends,
as for example, to provide restriction enzyme recognition
Sequences. Restriction enzyme recognition Sequences are
known to those with Skill in the art and can provide an
amplified product with restriction endonuclease recognition
Sequence at one or both ends of the amplified products.
Other Sequences can be added at one or both ends of the
primers to act as markers of the amplified products as, for
example, a universal primer Sequence.
Primers can also be designed that are not perfectly
complementary and Still can hybridize to a portion of the
target Sequence or flanking Sequence and thereby provide for
amplification of all or a portion of a target Sequence. Primers
of about 20 nucleotides or less preferably have about one to
three mismatches located at the 5' and/or 3' ends. Primers of
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Once the target Sequence has been identified, the target
Sequence can Serve as a probe or can be used to design other
probes. A probe can hybridize to all or a portion of a target
Sequence, preferably under all Stringency conditions. The
preferred probes hybridize to all or a portion of a 2.3 kb
HindIII partial digest restriction fragment of S. hyodysente
riae B204 as shown in FIG. 1. The probes are useful to
detect amplified products of the target Sequence and to detect
and identify at least one Serotype of S. hyodysenteriae.
A probe can have about 16 to about 2300 nucleotides,
more preferably about 25 to 100 nucleotides. A probe can
hybridize to all or a portion of a target Sequence. If a probe
is designed to detect amplified products of the target
Sequence, it is preferably designed not to hybridize to the
Sequence of primers used for amplification. A probe
designed to detect amplification products can preferably
hybridize to Sequences between the primer Sequences. A
probe can hybridize to the DNA strand with coding sequence
and is designated a Sense probe. A probe can hybridize to the
DNA strand that is complementary to the strand with the
coding Sequence and is designated an anti-Sense probe. A
probe can be designed to hybridize to mRNA complemen
tary to the target Sequence.
Hybridization conditions for forming hybrids for a probe
of about 16 to 100 nucleotides or more without any mis
matches are preferably those described in Flores et al., J. of

Vir, 64:4021 (1990). Briefly, immobilized target sequences
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are incubated at 53 C. for 16 to 32 hours in 4xSSC

(1xSSC=0.15M NaCl plus 0.015M sodium citrate), 0.02%

Sodium dodecyl sulfate, 50% formamide, 50 mM potassium
phosphate buffer, 10% Dextran sulfate, 0.02% Ficoll

(Pharmacia, Inc., Piscataway, N.J.), 0.02% bovine serum
60

albumin, 0.02% polyvinylpyrrolidone, 20 tug sheared salmon
DNA per ml, and the probe. Prehybridizations are carried

out in the same buffer minus dextran Sulfate. After
65

incubation, the hybrids are washed four times for 5 minutes
at room temperature with 0.1% sodium dodecyl sulfate in
2.5xSSC, and then twice for 15 minutes at 53 C. with
0.05% sodium dodecyl sulfate in 1.25xSSC. These condi
tions can be modified, if necessary, depending on the method
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of detection employed, Such as dot blot hybridization,
Southern blot hybridization, or multiwell solution hybrid
ization. Modification of hybridization conditions depending
on the method employed are known.
A probe of the invention can be perfectly complementary
to the target Sequence or can have Some mismatches with the
target Sequence. A probe of about 16 to 20 nucleotides
preferably has about 1 to 3 mismatches localized near the 5'
or 3' ends of the probe (i.e., within 5 base pairs of either end).
Probes of about 20 to 2300 nucleotides can have up to about
30% mismatches and still hybridize to the target sequence.
Mismatched probes can Still hybridize to the target Sequence
if conditions of hybridization are modified to account for the
mismatch, as, for example, by decreasing melting tempera
ture by about 1.0 to 1.5 C. for every 1% of mismatch.
Because a target DNA sequence has been cloned and
identified, the effect of mismatches in the probe on T.
(melting temperature) can be determined using a standard
method such as described by Maniatis at pages 11.47 to
11.57, which is hereby incorporated by reference.
Probes can also be detectably labeled using a variety of
standard methods. The probes can be detectably labeled by
incorporating one or more labeled nucleotides into the
probe. Nucleotides can be labeled with biotin, with a
radiolabel, or with a fluorescent moiety or luminescent
moiety and the like.
A preferred probe of the invention can hybridize to all or
a portion of a 2.3 kb HindIII restriction fragment of S.
hyodysenteriae B204 (SEQ ID NO:l) or to amplification
products of a 2.3 kb HindIII restriction fragment from
Serotype B204 and other Serotypes. A preferred probe has a
Sequence as follows:

12
The extract is then digested with at least one restriction
enzyme. The choice of restriction enzyme is based upon the
Sequence of the DNA target Sequence Specific for S. hyod
ySenteriae and the recognition Sequence of the restriction
enzyme. Recognition Sequences for restriction enzymes are
known to those of skill in the art. If all or a portion of the
DNA sequence of the target Sequence for S. hyodysenteriae
is known, then restriction enzymes can be Selected based on
that Sequence. For example, the Sequence of a 2.3 kb HindIII
target Sequence, shown in FIG. 1, indicates that there is one
site where HindIII can cut the sequence. Other restriction
enzymes can be selected that can cut the Sequence at one or
more locations, preferably at about 1 to 3 locations, as
shown in Table I.
15

TABLE I
Aci
Bby
BSmI
BSrBI

CePI
Eae
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Alw
BcgI
BSmBI
BSrGI

AlwNI
Bfa
BSOFI
Cac8

Apo
BSeRI
BspMI
CeI

Cvil

Cvr

Dde

DpnI

Dra

Ear

Eci

EcoS7

Econ

EcoRI

EcoRI

GdIII

Hae

HindIII

Hinf

Hph I

Mbo

Mme

Mn

Mise

Ms

MspI

MspAII

Mwo

NaIII

Nsi

NspI

Pwl

RsaI

Sau6

Sau3AI

SexAI

SfcI
Tsp5091

SspI
Tth

Taq I

Taq II
VspI

TI

SfaNI
Tse

(SEQ ID NO:5)

Alu
Bcc
BsmAI
BSFI

Mae

25 Pst

Sense-5'-TAGGGGCTGCTGTTCTAGCTGTAAATGC

and can hybridize to about a 1.5 kb amplification product of
S. hyodysenteriae B204 and other serotypes and to the 2.3 kb
HindIII fragment under low Stringency conditions.
Once designed, a probe can be prepared by automated
DNA Synthesis or by polymerase chain reaction using appro
priate primers. The probe can also be prepared by digesting
the 2.3 kb insert in pRED3C6 with any one or more of the
restriction enzymes shown in Table I.
A probe according to the invention can be used in a
method for identifying at least one Serotype of S. hyOdyS
enteriae or distinguishing S. hyodysenteriae from at least
one other microorganism. The probes are used in methods
Such as restriction enzyme, PCR amplification, Slot blot, dot
blot, and Southern blot analysis of DNA taken from bio
logical Samples Suspected of containing at least one Serotype
of S. hyodysenteriae. The steps of the method include
isolating DNA from a biological Sample Suspected of con
taining at least one Serotype of S. hyodysenteriae, digesting
the extracted DNA with at least one restriction enzyme, and
detecting any Sequence Specific to S. hyodysenteriae by
hybridization to a probe Specific for at least one Serotype of
S. hyodysenteriae chromosomal DNA.
The extraction of DNA from a biological sample can be
accomplished by Standard methods. Elder et al., cited Supra.
Biological Samples can include pure cultures of bacteria
isolated by Standard microbiological methods or a biological
Sample Suspected of having at least one Serotype of S.
hyOdysenteriae as well as other microorganisms. Examples
of biological Samples include feces, intestinal contents,
intestinal mucosal Scrapings, fecal Swabs and the like.
Environmental Samples are also biological Samples Such as
manure, manure-contaminated Soil, fomites, pits, lagoon
water, or effluent from a premises Suspected of containing S.
hyOdysenteriae.

AccI
Ava
BSI
BSr.

The digested DNA is then contacted with a probe that can
hybridize to a target Sequence Specific for at least one
serotype of S. hyodysenteriae under conditions of hybrid
ization for a probe of that size and/or Sequence complemen
tarity as described previously. The hybridization conditions
can be modified as necessary depending on the method of
detection of hybrid formation employed including slot blot,
dot blot, and/or Southern blot hybridization. The probes are
preferably labeled for ease of detection of hybrid formation.
In a preferred version, DNA is extracted from a biological
Sample Such as from an animal Suspected of being infected
with S. hyodysenteriae or from an environmental Sample
Suspected of containing S. hyodysenteriae and the extracted
DNA is digested with HindIII. The digested DNA extract is
optionally Separated and contacted with a probe that can
hybridize to a target Sequence Specific for S. hyodysenteriae
such as a 2.3 kb HindIII restriction fragment of FIG.1. The
preferred probe has a Sequence as follows:
Sense-5'-TAGGGGCTGCTGTTCTAGCTGTAAATGC

(SEQ ID NO:5)

50
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and is detectably labeled. The presence of S. hyodysenteriae
is detected by the detection of hybridization of the probe to
digested fragments from the biological Sample. Methods of
detection of hybrids can be utilized depending on the labeled
moiety that is attached to the probe, and are Standard
methods. This method can also be used to distinguish S.
hyOdysenteriae from at least one other microorganism.
2. Recombinant Expression Vectors and Transformed Cells
A target nucleotide Sequence that allows for identification
of at least one Serotype of S. hyodysenteriae can be cloned
into an expression vector and introduced into Suitable host
cells to form transformed cells. The transformed cells car

rying an expression vector are useful for amplification of all
or a portion of a target Sequence to provide a probe, to
provide any gene products encoded by the target Sequence,
and/or as vaccine formulations.
65

A target Sequence, Such as all or a portion of a 2.3 kb
HindIII partial digest fragment from S. hyodysenteriae B204

(SEQ ID NO:1), can be cloned into a suitable expression

5,869,630
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include Swine, ratites (Such as rheas), rodents such as rats
and mice, dogs, birds, poultry, and other wildlife.
The detection method can also be optionally combined
with methods for isolation of microorganisms to provide for
confirmation of infection with S. hyodysenteriae and/or to
increase the Sensitivity of the assay. For example, S. hyod
ySenteriae present in a biological Sample could be separated
from other biological material using an antibody attached to
a Solid Support Such as a monoclonal antibody attached to
immunomagnetic particle, as described by Islam et al., J.
Clin. Micro., 30:2801 (1992). The isolated S. hyodysenteriae
can then be detected using the polymerase chain reaction as

13
vector such as puC18, pKC30, pBR322, pKK177-3, pET-3,
and the like by standard methods. Commercially available
expression vectors provide for cloning for a target Sequence
into a site of the vector Such that the target Sequence is
operably linked to transcriptional and translational control
regions. It is preferred, but not required, that a target
Sequence is operably linked to an inducible promoter Such as
the PL promoter, the lac promoter, the tac promoter, or the
T, promoter, and the like.
The expression vectors can then be introduced into Suit
able host cells using methods Such as calcium phosphate
precipitation, lipoSome mediated transformation, protoplast
transformation, electroporation, and the like. Suitable host

described herein.

In a preferred method, the amplification of the DNA

cells include E. coli strains Such as E. coli DH5C, and

avirulent isogenic Salmonella spp. Such as S. typhimurium
deletion mutants lacking adenylate cyclase and cAMP
receptor protein, Salmonella mutants in aro genes, and other

15

described in U.S. Pat. No. 4,683,202 to Mullis; Mullis et al.,

Cold Spring Harbor Symp. Quanti. Biol. 51:263 (1896);
Mullis and Faloona, Methods Enzymol. 155:335 (1987);
Saiki et al., Science 239:487 (1988b); and Chien et al., J.
Bacteriol. 127:1550 (1976). In brief, the DNA sequence is

Salmonella vaccine strains as described in Bio/Tech, 6:693

(1988), and the like.

Transformed cells can be screened by a variety of meth
ods including colony hybridization or reactivity with anti
bodies specific for S. hyodysenteriae B204. A transformed
cell is an E. coli DH5O. cell carrying a puC18 plasmid with
a 2.3 kb HindIII restriction fragment insert from S. hyodys
enteriae B204. A pUC18 plasmid carrying a 2.3 kb HindIII
insert from S. hyodysenteriae B204 designated pRED3C6,
deposited with the American Type Culture Collection in

amplified by reaction with at least one oligonucleotide
primer or pair of oligonucleotide primers that hybridize to
the target Sequence or a flanking Sequence of the target

Sequence and a DNA polymerase to extend the primer(s) to
25

by (a) extracting DNA from a biological Sample; (b) ampli

The biological Sample is first treated to extract a nucleic
acid Sequence Specific to S. hyodysenteriae, which may be
either mRNA or DNA. The nucleic acid fragments may be
extracted from the biological Sample by Standard methods as
described in Elders et al., cited Supra. Either purified chro
mosomal DNA or total DNA or total mRNA is extracted

50

from the biological Sample for amplification and detection.
In addition, the polymerase chain reaction may be used to
amplify cl)NA that has been synthesized in vitro by reverse
transcriptase of an mRNA template, according to Standard
methods. The mRNA that is extracted from the biological
Sample for Synthesis of cDNA sequence is Suspected of
including a messenger RNA that is complementary to a
target Sequence Such as a 2.3 kb HindIII partial digest
restriction fragment of S. hyodysenteriae B204. Primers
useful to generate cDNA can be designed as described
previously.
Other methods of polymerase chain reaction using various
combination of primers including a single primer to about 3
primers are known to those of skill in the art and are
described in Maniatis, cited Supra. Those methods include
asymmetric PCR, PCR using mismatched or degenerate
primers, reverse transcriptase PCR, arbitrarily primed PCR

55

(Welsh et al., Nucleic Acids Res., 18:7213 (1990)), or RAPD
PCR, IMS-PCR (as described by Islam et al., J. Clin. Micro,
30:2801 (1992)), multiwell PCR (ELOSA) (as described by
Luneberg et al., J. Clin. Micro. 31:1088 (1993) and Katz et
al., Am. J. Vet. Res., 54:2021 (1993). The methods also
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fying a target Sequence of the extracted DNA to provide
DNA amplification products carrying a Selected target DNA

Sequence; and (c) detecting the presence of S. hyodysente

riae by detecting the presence of the DNA amplification
products.
The biological Sample may be, for example, feces,
mucosal Secretion, mucosal Scrapings, mucosal cells, rectal
Swabs, intestinal wall, intestinal contents, local lymph
nodes, and the like. The biological Sample may be derived,
for example, from an animal infected with S.
hyOdysenteriae, an animal Suspected of being a carrier of S.
hyOdysenteriae, an animal being treated for an infection
caused by S. hyodysenteriae. The biological Sample can also
be an environmental Sample Such as manure, manure
contaminated Soil, fomites, pits, lagoon water, or effluent
from a premises Suspected of containing S. hyodysenteriae.
Animals susceptible to infection with S. hyodysenteriae

amplify the target Sequence. The amplification cycle is
repeated to increase the concentration of the target DNA

Sequence.

Rockville, Md. has Accession No. 75826.

3. Method for Detection of S. hyodysenteriae in a Biological
Sample
According to the invention, a biological Sample may be
analyzed for the presence of S. hyodysenteriae by detecting
the presence of DNA amplification products from primers
that hybridize to a 2.3 kb HindIII partial digest restriction
fragment of S. hyodysenteriae B204 serotype 2. Compared
to other detection methods presently known and used, the
invention advantageously provides a method that is highly
Sensitive in detecting at least one Serotype of S. hyodysen
teriae in a biological Sample when it is present in very low
concentration, for example, about 1 to 10 organisms per 0.1
gm sample. It is preferred that an about 1.55 kb DNA
Sequence that lies between two regions of the about 2.3 kb
HindIII Sequence is amplified. That Sequence is unique to all
Serotypes of S. hyodysenteriae, and provides for the Specific
detection of the Spirochete from other closely-related micro
organisms including other members of the order Spirocha
etales. Thus, this method is also useful to distinguish S.
hyOdysenteriae from at least one other microorganism.
In brief, the DNA amplification products can be detected

Sequence is by polymerase chain reaction (PCR), as

include amplification using a Single primer as described by

Judd et al., Appl. Env: Microbiol., 59: 1702 (1993).
60

The nucleotide Sequences are recovered from the biologi
cal Sample So as to be Substantially free of Substances that
may interfere with the enzymatic amplification procedure, as
for example, enzymes, low molecular weight Substances
Such as peptides, proteins, lipids, carbohydrates, and the

like. Such methods are known and used in the art.
65

In a preferred version, an oligonucleotide primer pair that
can hybridize to the 2.3 kb HindIII restriction fragment of S.
hyodysenteriae B204 shown in FIG. 1 are mixed with
deoxynucleotides, Taq polymerase, and the extracted DNA

5,869,630
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or CDNA. Initial denaturing is at 95 C. for 60 seconds
followed by 30 cycles with 60 seconds at 65° C. and 120
Seconds at 72 C. Amplified products are optionally sepa
rated by methods Such as agarose gel electrophoresis. The
amplified products can be detected by either Staining with
ethidium bromide silver stain or by hybridization to a probe
as described previously. The preferred oligonucleotide
primer pairs amplify a portion of the target Sequence of S.
hyodysenteriae B204 of FIG. 1 to form an about 1.5 kb
amplification product.
In an alternative embodiment, at least one probe that
hybridizes to the amplified products is labeled with a biotin
moiety and/or at least one probe labeled with fluorescently
labeled probe. The hybrids are then bound to a solid support
Such as a bead, multiwell plate, dipStick or the like that is
coated with streptavidin. The presence of bound hybrids can
be detected using an antibody to the fluorescent tag conju
gated to horseradish peroxidase. The enzymatic activity of
horseradish peroxidase can be detected with a colored,

16
gene Sequences may be visualized, for example, by Sepa
rating the gene Sequences from undesirable Side-products
and unreacted reagents by electrophoresis in an agarose or
polyacrylamide gel, by HPLC Separation in an ion eXchange
column or size exclusion column, or by the ELOSA
technique, and other like techniques known and used in the
art.
The amplified gene Sequence may be directly or indirectly
labelled by incorporation of an appropriate visualizing label,
as for example, a radioactive, calorimetric, fluorometric or
luminescent Signal, or the like. In addition, the gel may be
Stained before or after electrophoresis with a visualizing dye
Such as ethidium bromide or silver stain wherein the result
15

luminescent or fluorimetric Substrate. Conversion of the

Substrate to product can be used to detect and/or measure the
presence of S. hyodysenteriae PCR products.
An oligonucleotide primer preferably has a gene Sequence
that hybridizes to a sequence flanking one end of the DNA
Sequence to be amplified. The DNA sequence to be ampli
fied is located adjacent the attachment of the Single primer,
or between the attachment of the two primers. In the use of
a pair of oligonucleotide primers, each of the primerS has a
different DNA sequence and hybridizes to Sequences that
flank either end of the target Sequence to be amplified.
Design of primers and their characteristics have been
described previously. The preferred DNA sequence of the
Oligonucleotide prime r is positive - Sense

5'-GGTACAGGCGGAAACAGACCTT (SEQ ID NO:3), or
negative-sense 5'-TCCTATTCTCTGACCTACTG (SEQ ID
NO:4), or a complement thereof, or a mixture thereof. The

primer may also be a degenerate primer that hybridizes to
the target gene Sequence under hybridization conditions for
a primer of that size and Sequence complementarity.
For the binding and amplification, the sample DNA is
provided in an aqueous buffer formulated with an effective
amount of a divalent cation which is preferably MgCl,
preferably at a concentration of about 0.05–5mM; an effec
tive amount of DNA polymerase with Taq DNA polymerase
being preferred in the form of native purified enzyme or a

reverse blotting hybridization (dot blot) in which an oligo
nucleotide probe Specific to the gene Sequence is adhered to

a nitrocellulose or polyvinylchloride (PVC) support such as
25
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Synthesized form Such as Ampli-Taq (available commer
cially from Perkin-Elmer Cetus Corp., San Francisco, Calif.)
an effective amount of dNTPs as a nucleotide Source,

including, dATP, dCTP, dGTP and dTTP, preferably in a
Saturating concentration, preferably about 200 uM per
dNTP; and an effective amount of one or a pair of oligo
nucleotide primers. The reaction mixture containing the

50

annealed primer(s) is reacted with a DNA polymerase at
about 72 C for about 1-10 minutes, preferably about 3-5

minutes, to extend the primers to make a complementary
Strand of the target gene Sequence. The cycle is then repeated
by denaturing the DNA Strands with heat, annealing and
extending, preferably for about 25-40 cycles, preferably
about 30 cycles.
The major resulting product is preferably an about 1.55 kb
gene Sequence which termini are defined by the oligonucle

55

60

otide primer(s), and whose length is defined by the distance

between the two primers or the length of time of the
amplification reaction. The gene Sequence then Serves as a
template for the next amplification cycle.
The amplified DNA products are optionally separated
from the reaction mixture and then analyzed. The amplified

ing bands may be visualized under ultraViolet light.
The amplified DNA products may also be detected by
Southern blot assay, dot blot assay, Slot blot assay, or other
like analysis, in which the amplified products are separated
by electrophoresis on a polyacrylamide or agarose gel,
transferred to a membrane Such as a nitrocellulose or nylon
membrane, reacted with an oligonucleotide probe, and
detected. The amplified products may also be detected by
a multi-Well plate, and then the Sample containing labelled
amplified product is added, reacted, washed to remove
unbound Substance, and a labelled amplified product
attached to the probe or the gene Sequence imaged by
standard methods. For slot blot analysis, the DNA products
may be applied to a nylon membrane using a microfiltration
apparatus, and hybridized with a labelled oligonucleotide
probe, as described by Standard methods.
The PCR amplification products can be detected in a
multiwell plate by hybridization to a probe Specific for S.
hyodysenteriae such as described in ELOSA methods by
Katz et al., cited Supra. For analysis of nucleic acids
extracted from more than one biological Sample, amplified
products of each extract may be placed Separately into a
different well of a multi-well plate, such as a PVC plate, and
coated with a capture molecule Such as Streptavidin. The
amplified products Specific for S. hyodysenteriae in each
well can be preferably detected by hybridization to a probe
labelled with a moiety that provides for color change Such as
a fluorescent-labelled probe. A multi-well plate format
allows the Screening of many different biological Samples in
a single plate and can be conducted because of the extreme
sensitivity of the PCR assay for detection of 1 to 10
organisms per 0.1 gram of feces or other biological Sample.
A multi-Well format likewise allows for the Screening and
quantitation of the target Sequence of a single Sample in a
Series of dilutions.

In those assays, the amplified products are hybridized
with an oligonucleotide probe that hybridizes to the target
gene Sequence. It is preferred that the oligonucleotide probe
is hybridizable to an about 1.5 kb gene Sequence located
within the about 2.3 kb HindIII partial digest restriction
fragment of the chromosomal DNA of S. hyodysenteriae
B204. The probe is hybridizable to all or a portion of the
gene Sequence under conditions Suitable for a probe of that
Size and Sequence complementarity. The probe can distin
guish from other microorganisms and cells in a biological
Sample. Preferably, the oligonucleotide probe, Specific to S.
hyodysenteriae has the Sequence: positive-Sense

5'-TAGGGGCTGCTGTTCTAGCTGTAAATGC (SEQ ID
NO:5). Other probes including detectably labelled probes
65

may be prepared as described previously.
ExceSS probe is removed from the reaction vessel or
Support, for example, by Washing with a Suitable Solution.

5,869,630
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The presence or absence of the DNA gene product is then
determined by visualization of the label on the membrane or
the vessel with an imaging System corresponding to the label
that is used, including, for example, autoradiography, radia
tion counting, X-ray, colorimetric, fluorometric or lumines
cent Signal, and the like.
The detection of amplified gene product in the Sample
indicates the presence of S. hyodysenteriae in the biological
Sample and in the animal. The method is useful in diagnos
ing an S. hyodysenteriae infection in animals, and for
detecting animals that are carrier-Shedders of S. hyodysen
teriae in that they have no outward Signs of disease but carry
the Spirochete internally and shed the organism in feces and
other body materials and for detecting S. hyodysenteriae in
environmental Samples contaminated with body fluids from

that the polypeptide has been extracted and isolated from its
natural association with other proteins, lipids, and other like
Substances from an appropriate host System. Preferably, the
DNA fragment has the nucleotide sequence shown in FIG.

1 (SEQ ID NO:1).

The polypeptide may be produced, for example by incor
porating the DNA restriction fragment into an expression
vector, which includes the restriction fragment operably
linked to transcriptional and translational control regions in
the vector. The expression vector may then be used to form
a transformed cell that includes the DNA fragment which
can be used to produce the 56 kDa polypeptide, as described
previously. The 56 kDa polypeptide has a predicted amino

acid sequence as shown in FIG. 1 (SEQID NO:2). A plasmid

15

infected animals.

The amplification method is also useful for monitoring the
efficacy of treatment for an infection caused by S. hyOdyS
enteriae to ensure that Subclinically infected or carrier
Shedder animals are not formed. For example, the assay may
monitor the effectiveness of treatment of an animal with an

antimicrobial agent Such as carbadox, tiamulin, lincomycin,
arSanilic acid, chlortetracycline, Oxytetracycline, bacitracin,
pyrantel tartrate, fenbendazole, gentamicin, neomycin,
roXarSone, tylosin, Sulfamethazine, Virginiamycin, and the
like, or a disinfection of the environment using agents Such
as chlorhexidine, formaldehyde, creSols, phenols and qua
ternary ammonium compounds among other treatments. In
that method, biological Samples Such as feces, rectal Swabs,
mucosal Scrapings, environmental Samples, and the like, are

saline (0.85%), phosphate-buffered saline (PBS), Tris
(hydroxymethyl aminomethane (TRIS), Tris-buffered
25

Freund's Incomplete Adjuvant (FCA), liposomes, ISCOMs
(Mowat et al., Immunology Today, 12:383 (1991)), EMUL

35

obtained from the animal from time to time on a routine

basis over the course of treatment, or afterwards, preferably
about every day following treatment. The method can be
used to monitor the efficacy of disinfection of equipment,
fomites and the environment Surrounding an animal infected
with S. hyodysenteriae.
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4. Vaccine.

A56 kDa polypeptide and nucleotide Sequence of a 2.3 kb
fragment of S. hyodysenteriae B204 shown in FIG. 1 are
useful in formulating vaccines for immunizing animals
against infection by S. hyodysenteriae. The polypeptide is
also useful in Stimulating antibodies Specifically reactive
with all the serotypes of S. hyodysenteriae and not with other
closely related non-pathogenic intestinal Spirochetes. The
vaccine contains an amount of the 56 kDa polypeptide
effective to elicit a protective immune response against S.
hyOdysenteriae in the animal, and achieving clinical efficacy,
by Stimulating the production of antibodies specifically
reactive with S. hyodysenteriae, exemplified by monoclonal

antibody 10G6/G10 (available from Dr. Duhamel at Uni
versity of Nebraska, Lincoln, Nebr.). The effectiveness of
the vaccine is due, at least in part, to the conservative nature
of the nucleotide Sequence encoding the 56 kDa polypeptide
between different serotypes of S. hyodysenteriae and to its
uniqueness to S. hyodysenteriae.
The vaccine is composed of a Substantially pure, 56 kDa
polypeptide encoded on an about 2.3 kb HindIII restriction
fragment of the chromosomal DNA of S. hyodysenteriae,
exemplified by the chromosomal DNA of S. hyodysenteriae
isolate B204 shown in FIG. 1. The 56 kDa protein has a

predicted amino acid sequence shown in FIG. 1 (SEQ ID
NO:2). As used herein, the term “substantially pure” means

Saline, and the like.

The vaccine may further include an adjuvant to enhance
the immune response in the animal. Such adjuvants include,
for example, aluminum hydroxide, aluminum phosphate,

obtained from an animal under treatment for an infection

caused by S. hyodysenteriae or the environment of the
animal, and DNA amplification products of a target
Sequence of S. hyodysenteriae from those Samples are ana
lyzed for the presence of the S. hyOdysenteriae. Samples are

designated pRED3C6 and carrying the 2.3 kb HindIII insert
from S. hyodysenteriae B204 has been deposited with the
American Type Culture Collection, Rockville, Md., and
given Accession No. 75826.
The polypeptide is administered in combination with a
physiologically-acceptable, non-toxic, liquid carrier, com
patible with the polypeptide and the animal. Suitable phar
macological carriers include, for example, physiological

SIGEN PLUS, and the like. The vaccine may also include
additives Such as buffers and preservatives to maintain
isotonicity, physiological pH, stability, and Sterility.
Parenteral and intravenous formulations of the vaccine may
include an emulsifying and/or Suspending agent, together
with pharmaceutically-acceptable diluents to control the
delivery and the dose amount of the vaccine. Other additives
may be included as desired, as for example, preservatives,
buffering agents, and the like.
The vaccine may be used for alleviating or minimizing the
Symptoms of an infection caused by S. hyodysenteriae. The
vaccine may be delivered to the animal, for example, by

parenteral delivery, injection (Subcutaneous or
intramuscular), oral, intrarectal, and the like, by known
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techniques in the art. For prophylactic and anti-infectious
therapeutic use in Vivo, the vaccine contains an amount of
the polypeptide to Stimulate a level of active immunity in the
animal to inhibit and/or eliminate S. hyodysenteriae patho
genesis.
Factors bearing on the vaccine dosage include, for
example, the age and weight of the animal. The range of a
given dose is about 1 to 1000 ug of the purified polypeptide
per ml, preferably about 50-200 tug/ml preferably given in

about 1-5 ml doses. The vaccine should be administered to
the animal in an amount effective to ensure that the animal

will develop an immunity to protect against infection by S.
hyodysenteriae. For example, for an about 20-30 lb Swine,
a single dose of a vaccine made with Freund's incomplete
adjuvant for Subcutaneous or intramuscular injection, would
contain about 50-200 tug of the purified polypeptide per ml.
Preferably, the vaccine is given in an about 1-5 ml dose

before or at the time of weaning (2-4 weeks old). The
65

immunizing dose would then be followed by a booster
injection given at about 14-28 days after the first injection.
The invention also provides for a vaccine formulation of
a live avirulent microorganism transformed with a vector
having a 2.3 kb DNA fragment insert from S. hyodysenteriae

5,869,630
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B204 having a nucleotide sequence as shown in FIG.1. The
fragment can be inserted in to a Suitable expression vector
such as pYA292, as described previously. Plasmid pYA292
carries a Salmonella origin of replication, an asd gene as the
only Selectable marker gene, P, regulator/promoter, a ribo
Some binding Site, and an ATG start codon followed by a
multiple cloning Site and transcriptional terminators. Plas
mid pYA292 is designed to express a recombinant antigen as
a non-fusion protein.
An expression vector carrying an insert can be trans
formed into an avirulent immunogenic host cell Such as
Salmonella spp. having attenuating mutations in genes
encoding enzymes involved in the Synthesis of Vital metabo
lites Such aro, cya, crp, and asd as described by Curtis et al.,

Spleen cell preparation can be fused with myeloma cells to
produce hybridomas. The hybridomas may then be cultured
and the culture fluid tested for antibodies specific for the 56
kDa polypeptide using, for example, an ELISA in which the
56 kDa polypeptide is immobilized onto a solid surface and
act as capture antigens. The hybridoma may then be intro
duced into the peritoneum of the host Species to produce a
peritoneal growth of the hybridoma, and ascites fluids con
taining the monoclonal antibody Specific to the Spirochete
may be collected.
The monoclonal antibodies may be used in diagnostic and
therapeutic compositions and methods, including passive
immunization. Immunoglobulins Specific towards the 56
kDa polypeptide may be used to provide passive immunity
against an infection caused by S. hyodysenteriae. Animals
may be treated by administering immunoglobulins intramus
cularly at about 100/mg/kg body weight, about every 3-7
days.
Diagnostic Method
Antibodies to the 56 kDa polypeptide may be used in an
in vitro method of diagnosing an infection of S. hyodysen
teriae in an animal. The diagnostic method includes con
tacting a body material potentially containing S. hyodysen
teriae Such as feces, mucosal Scraping, or other like tissue
sample or body material with a labelled antibody raised to
the 56 kDa polypeptide encoded on an about 2.3 kb HindIII
restriction fragment of S. hyodysenteriae, and detecting the
label in the complex formed between the polypeptide in the
body material and the labelled antibody. The method may
also be performed by combining the body sample with the
antibody to the polypeptide, and then contacting the Sample
with a labelled anti-species antibody reactive with the
polypeptide-specific antibody, and then detecting the label.
In addition, the 56 kDa polypeptide may be used as a
capture antigen in a method of monitoring and profiling an
infection caused by S. hyodysenteriae. For example, the
polypeptide may be used in an ELISA technique by immo
bilizing the polypeptide on a Solid Support Such as a poly
Vinylchloride plate, and contacting the immobilized peptide
with a Sample material to react with and detect antibodies
present in the Sample.
The invention further provides an in vitro assay for
detecting S. hyodysenteriae-specific antibodies in a Sample.
In that method, a Sample to be tested is contacted with a
composition containing the about 56 kDa polypeptide,
which is preferably labelled, to form a conjugate which is
then detected. A method for diagnosing an infection by S.
hyOdysenteriae in a biological Sample may be carried out
with the polyclonal antibody Sera or monoclonal antibodies
described hereinabove, in an enzyme-linked immunosorbant

Infection and Immunity, 55:3035 (1987); Dugan et al., J.
Infec. Dis., 158:1329 (1988); and Edwards et al., J.
Bacteriol, 170:3991 (1988). These microorganisms have

15

tide encoded by the 2.3 kb insert (SEQ ID NO:1) can be
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the capacity to elicit long-lasting humoral and cell mediated
immunity at high levels of Safety.
The Salmonella spp. transformed with a vector carrying a
2.3 kb insert from S. hyodysenteriae can be screened for
reactivity with antibodies to S. hyodysenteriae or by hybrid
ization of DNA or mRNA to a probe specific for the 2.3 kb
insert. Transformed Salmonella spp. producing a polypep
further Selected for avirulence and for generating a protec
tive immune response against S. hyodysenteriae in an ani
mal. Animals include Swine, poultry, ratites, rodents, birds,
rheas, and the like. The transformed microorganism that is
avirulent and elicits a protective immune response against S.
hyOdysenteriae infection in an animal is the preferred micro
organism for the vaccine formulation.
The microorganisms can be combined with carriers or
adjuvants as described previously. The vaccine can be
administered parenterally, e.g. Subcutaneously, intraperito
neally or intramuscularly, orally or intra-rectally. Preferably,
the vaccine is administered orally at least one and preferably
at least two or more times at intervals of about 14 to 28 days.
The amount of microorganism included in the vaccine
formulation is an amount that is effective to generate a
protective immune response against infection with S. hyo
dysenteriae as determined by detecting a decrease in the
mortality and/or Symptoms of disease caused by S. hyOdyS
enteriae. The amount of microorganisms will depend, in
part, on the route of administration and/or the animal to
immunized. Preferably, an amount of microorganisms is
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about 10 to 10 CFU/ml and more preferably about 10 to
10 CFU/ml.

Passive Immunization

The polypeptide may also be utilized to raise polyclonal
antibody Sera and monoclonal antibodies for use in passive
immunization therapies. Polyclonal antibodies may be
raised to the polypeptide by hyperimmunizing an animal
with an inoculum containing the isolated 56 kDa polypep
tide. The blood serum may be removed and contacted with
immobilized 56 kDa polypeptide reactive with the protein
Specific antibodies. The Semi-purified Serum may be further
treated by chromatographic methods to purify IgG and IgM
immunoglobulins to provide a purified polyclonal antibody

50

Sera for commercial use.
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Monoclonal antibodies reactive with the polypeptide may
be raised by hybridoma techniques known and used in the
art. In brief, a mouse, rat, rabbit or other appropriate Species
may be immunized with the 56 kDa polypeptide. The spleen
of the animal is then removed and processed as a whole cell
preparation. Following the method of Kohler and Milstein

(Nature 256:496–97 (1975)), the immune cells from the
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assay (ELISA), radioimmunoassay (RIA), immunofluores
cent assay (IFA), a Northern, Western or Southern blot assay,
and the like. In brief, the antibody or biological Sample (i.e.,
tissue sample, body fluid) may be immobilized, for example,

by contact with a polymeric material Such as polystyrene,
polyvinylchloride, a nitrocellulose paper, or other like Sup
port means for immobilizing the antibody or Sample. The
other antibody or biological Sample is then added, incubated,
and the non-immobilized material is removed by Washing or
other means. A labeled Species-specific antibody reactive
with the later is added. The serum antibody or S. hyodys
enteriae bacteria in the biological Sample, is then added and
the presence and quantity of label is determined to indicate
the presence and amount of S. hyodysenteriae bacteria in the
biological Sample.
5. Mutants of S. hyodysenteriae and Vaccine Composition
Once a target Sequence Specific for S. hyodysenteriae and
that can distinguish at least one Serotype of S. hyodysente

5,869,630
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riae from other closely related microorganisms is identified,
the target Sequence can be altered or mutated to form
mutants of S. hyodysenteriae. An example of a target
Sequence is found in all Serotypes of S. hyodysenteriae and
not in other closely-related microorganisms is a 2.3 kb
HindIII restriction fragment of S. hyodysenteriae serotype
B204 having the nucleotide sequence shown in FIG. 1. S.
hyodysenteriae B204 mutants with alterations in the
Sequence shown in FIG. 1 can be generated using Standard
methods. Mutants with alterations or deletions in this region
can be selected for reduced virulence and/or the ability to
Stimulate an immune response, preferably a protective
immune response to infection with S. hyodysenteriae Sero
types. These mutants can be useful in vaccine formulations
and to elicit antibodies in animals without causing mortality.
The antibodies elicited could be used for passive immuni

22
pharmacological carriers include, for example, physiologi

cal saline (0.85%), phosphate buffered saline, Tris
(hydroxymethylamino methane), Tris buffered Saline, and
the like.

The vaccine may further include an adjuvant to enhance
the immune response in the animal. Such adjuvants include,
for example, aluminum hydroxide, aluminum phosphate,
Freunds incomplete adjuvant, liposome, ISCOMs,
EMULSIGEN, and the like. The vaccine may also include
additives Such as buffers and preservatives to maintain
isotenicity physiological pH instability. Parental and intra
venous formulations of the vaccine may include emulsifying
and/or Suspending agent together with pharmaceutically
acceptable diluents to control the delivery and dose amount
15

The vaccine may be used for alleviating or minimizing the
Symptoms of disease caused by S. hyodysenteriae. The
vaccine may be delivered to the animal, for example, by

Zation.

Mutants of S. hyodysenteriae B204 with alterations in the
2.3 kb HindIII restriction fragment can be generated using

Standard methods Such as chemical mutagenesis (as
described in U.S. Pat. No. 4,999,191 to Glisson et al.);
transposon mediated mutagenesis (as described in U.S. Pat.
No. 4,764,370 to Fields et al.); ultraviolet irradiation; and
methods of site-specific mutagenesis (as described in Mania
tis et al., cited Supra).

Mutant microorganisms can be Screened for alteration to
the target Sequence in a 2.3 kb HindIII restriction fragment
using a variety of methods. The mutant can be Screened
preferably for lack of production of a functional gene
product encoded by a 2.3 kb HindIII restriction fragment by
lack of reactivity with an antibody Specific for all or a
portion of the polypeptide encoded by the fragment as
exemplified by monoclonal antibody 10G6/G10 or poly
clonal antibodies to the peptides, as described in Example
VI. The mutants can also be screened for an inability to
hybridize to a 2.3 kb HindIII restriction fragment probe or
a change in the restriction enzyme fragments that hybridize
to the probe. Other Screening methods, Such as using PCR
and Sequencing of the mutated fragment, can also be
employed.
Alterations or mutations to the target Sequence include

parental delivery, injection (Subcutaneous or intramuscular),

25

given dose is about 10 to 10' CFU of the microorganism
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EXAMPLE I

Bacterial Culture and Growth Conditions
45
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Serpulina hyodysenteriae strain B78 serotype 1 (ATCC#
27164; Harris et al., Int. J. Syst. Bact., 29:102-109 (1979);
and Kinyonet al., Infect. Immun., 15:638-646 (1977)), strain

B204 serotype 2, strain B169 serotype 3, and strain A1
serotype 4, were obtained from J. M. Kinyon, College of
Veterinary Medicine, Iowa State University, Ames, Iowa.
Reference S. hyodysenteriae strains B234 serotype 1, B8044
serotype 5, B6933 serotype 6, AcK300/8 serotype 7 were
provided by L. A. Joens, Department of Veterinary Science,
University of Arizona, Tucson, Ariz. Reference Strains
FM-88-90 serotype 8, FMV 89-3323 serotype 9 were pro
vided by M. Jacques, Faculté de Médecine Vétérinaire,
Université de Montréal, Saint-Hyacinthe, Québec, Canada.

Li et al., J. Clin. Microbiol., 29:2794–2797 (1991). The

animals, wherein the mutation is an alteration of a 2.3 kb

HindIII restriction fragment of S. hyodysenteriae B204 in
admixture with a physiologically acceptable carrier. The
mutant microorganism is administered in combination with
a physiologically acceptable, non-toxic liquid carrier com
patible with the microorganism and the animal. Suitable

Several genera of bacteria were cultured and grown to
provide nucleic acid Samples for analysis by polymerase
chain reaction and Southern blot hybridization with the 2.3
kb HindIII DNA fragment of clone pRED3C6.
1. Bacterial Strains.

The mutants of the invention can also be useful in vaccine
formulation. A vaccine formulation includes an amount of a

mutant of S. hyodysenteriae having reduced virulence for
animals effective to inhibit S. hyodysenteriae infection in

given in about 1 to 5 ml doses. The vaccine can be
administered to the animal as a single dose but is preferably
administered as 2 or 3 doses over an 8-10 week period.
The invention will be further described by reference to the
following detailed examples, wherein the methodologies are
as described below. These examples are not meant to limit
the scope of the invention that has been set forth in the
foregoing description. Variation within the concepts of the
invention are apparent to those skilled in the art. The
disclosures of the cited references throughout the Specifica
tion are incorporated by reference herein.
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The mutants of the invention are useful to elicit antibodies

in animals without causing mortality. These antibodies can
be useful in methods of passive immunization as described
previously.

or oral delivery by techniques known in the art. For pro
phylactic and anti-infectious therapeutic use in Vivo, the
vaccine contains an amount of the microorganism effective
to Stimulate a level of active immunity in the animal to
inhibit and/or eliminate S. hyodysenteriae pathogenesis.
Factors bearing on the vaccine dosage include, for
example, the age and weight of the animal. The range of a

per ml, preferably about 10 to 10 CFU/ml, preferably

nucleotide Substitutions, deletions, additions (i.e., especially
insertion of a transposon) in the 2.3 kb HindIII restriction

fragment of serotype B204. Once mutants with alterations to
the Sequence are identified, they can be further Selected for
reduced virulence in animals and for the ability to elicit an
immune response, preferably a protective immune response,
using Standard methods. The especially preferred mutants
have a deletion of a portion of a 2.3 kb HindIII restriction
fragment, have reduced virulence for animals, and elicit a
protective immune response that inhibits wild-type S. hyo
dysenteriae infection with at least one Serotype of S. hyod
ySenteriae.

of the vaccine.

reference isolates for WBHIS, Serpulina innocens, isolates

B256 (ATCC#29796; and Harris et al., cited supra) and 4/71
65

were obtained from the American Type Tissue Culture
Collection, Rockville, Md., and T. B. Stanton, National Pig
Disease Center, Ames, Iowa, respectively.

5,869,630
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A total of 13 field isolates representing three genotypic
groups of WBHIS distinct from S. innocens were obtained
from porcine feces, porcine rectal Swabs, and porcine
colonic mucosal Scrapings Submitted either to the Veterinary
Diagnostic Center, University of Nebraska-Lincoln or Agri
culture Canada, Saint-Hyacinthe, Québec. Lee et al., Vet.

EXAMPLE II

Library Construction and Recombinant Screening
5

Microbiol, 34:35-46 (1993); and Ramanathan et al., Vet.
Microbiol, 37:53–64 (1993). The WBHIS isolates B359 and

1. Preparation of the DNA Library.
Serpulina hyodysenteriae isolate B204 and weakly
B-hemolytic intestinal spirochetes of Swine; isolates B359

B1555a were obtained from J. M. Kinyon, and isolate
D9201243A was provided by R. L. Walker, California
Veterinary Diagnostic Laboratory System, University of

California, Davis, Calif. The WBHIS isolate 16 (ATCC#
49776; Jones et al., J. Clin. Microbiol., 24:1071-1074
(1986)) obtained from an HIV-positive homosexual male

with diarrhea was provided by R. M. Smibert, Virginia
Polytechnic Institute, Blacksburg, Va. In addition, species of
other genera of bacteria were obtained and cultured accord
ingly to Standard methods as described below. In Some

15

at 37° C.

DNA was isolated, by a modification of a previously

25

a final concentration of 1 mM and the mixture was incubated
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at room temperature for 10 minutes, then the Solution was
mixed with 0.1 Volume of 7.5M ammonium acetate, and the
DNA was precipitated with 2 volumes of ethanol. The DNA
precipitate was recovered on a glass rod, washed with 70%
ethanol, resuspended in TE buffer to a concentration of 0.5
to 1 lug/ul and stored at -20° C. until needed.
Standard cloning protocols were used for DNA manipu
lations. Sambrook et al., Molecular Cloning. A Laboratory
Manual, 2nd ed., Cold Spring Harbor Laboratory, Cold

Spring Harbor, N.Y. (1989). Purified chromosomal DNA
from S. hyodysenteriae, isolate B204 was incompletely
digested with HindIII (Stratagene, Lajolla, Calif.) and 4 kb
45
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logarithmic phase in 5 ml Volumes in Hungate tubes or in

250 ml volumes in serum bottles. Cultures were stirred

constantly using a magnetic stirrer at 37 C. under a 10%
hydrogen, 10% carbon dioxide and 80% nitrogen atmo
sphere for 48 to 72 hours. Cultures of Salmonella spp.,
Bacteroides vulgatus and Escherichia coli were grown at
37 C. with shaking in Luria-Bertani broth to late logarith
mic phase.
Chromosomal DNA was purified as previously described
by Ramanathan et al., Vet. Microbiol, 37:53-64 (1993),
except that the final pellet was resuspended in Sterile HO to
a final concentration of 12.5 ng/ul.

reported method (Caputa et al., J. Clin. Microbiol.,
29:2418–2413 (1991)), from a 500 ml culture of S.
hyodysenteriae, isolate B204. Briefly, spirochetes were
centrifuged, washed twice in 100 ml of TE buffer (10 mM
Tris-HCl pH 8.0), 1 mM Na-EDTA pH 8.0), and resus
pended in 25 ml of 50 mM Tris-HCl (pH 8.0), 50 mM
Na-EDTA (pH 8.0). N-lauroylsarcosine was added to a final
concentration of 2% (wt/vol), followed by the addition of
100 tug/ml of proteinase K. The mixture was incubated at 56
C. for 16 hours. Phenylmethylsulfonyl fluoride was added to

2. Medium and growth conditions.
For isolation of DNA, cultures of Serpulina spp., WBHIS,
and T. SuccinifacienS were propagated in pre-reduced

anaerobically-sterilized (PRAS) trypticase soy broth supple
mented with 0.5% (wt/vol) glucose (Sigma Chemical Co.,
St. Louis, Mo.), 0.05% (wt/vol) cysteine hydrochloride
monohydrate (Sigma), 1.0% (wt/vol) yeast extract (BBL
Microbiology Systems, Becton Dickinson and Co.,
Cockeysville, Md.), 2.0% (v/v) bovine fetal serum (HyClone
Laboratories, Inc., Logan, Utah), 0.2% (wt/vol) sodium
bicarbonate and 5.0% (v/v) sterile porcine fecal extract as
described by Kunkle et al., J. Clin. Microbiol., 24:669-671
(1986), except that 1% (vol/vol) of room air was injected at
the time of inoculation (Stanton et al., Vet Microbiol.,
18:177-190 (1988)). Broth cultures were grown to late

were used. Serpulina spp. and other Spirochetes were propa

24:669–671 (1986)) to a density of 10 to 10° cells per ml

Treponema succinifaciens, isolate 6091 (ATCC# 33096;
Cwyk et al., Arch. Microbiol., 122:231-239 (1979)) and
Bacteroides vulgatus (ATCC# 31376) were obtained from

chased from a commercial source (GIBCO-BRL,
Gaithersburg, Md.).

and B1555a (courtesy of J. M. Kinyon, College of Veteri
nary Medicine, Iowa State University, Ames, Iowa); Ser
pulina innocens isolate B256 (American Type Culture
Collection, Rockville, Md.); and E. coli strain DH5C.
(Bethesda Research Laboratories, Inc., Gaithersburg, Md.)
gated in FS medium (Kunkle et al., J. Clin. Microbiol.,

instances, chromosomal DNA was obtained.

the American Type Tissue Culture Collection. Chromosomal
DNA from Spirochaeta aurantia was provided by E. P.
Greenberg, University of Iowa, Iowa City, Iowa. The Tre
ponema pallidum chromosomal DNA was provided by M. V.
Norgard, The University of Texas Health Science Center,
Houston, Tex. Chromosomal DNA from representative
Stains of each of the ten genetic groups in the family
Leptospiraceae including Leptospira biflexa Serovars patoc,
Semaranga, and codice, Leptospira interrogans Serovars
icterohaemorrhagiae, fortbragg, ballum, celledoni, lyme,
and borincana, and Leptonema illini Serovar illini were
provided by R. L. Zuerner, National Pig Disease Center,
Ames, Iowa. Chromosomal DNA from Borrelia burgdorferi,
Campylobacter coli and C. hyointestinalis were provided by
M. P. Murtaugh, University of Minnesota, St. Paul, Minn.
Isolates of Salmonella choleraeSuis and S. typhimurium
were provided by P. J. Fedorka-Cray, National Pig Disease
Center, Ames, Iowa. The Escherichia coli DH5C. was pur

A library of S. hyodysenteriae isolate B204 in E. coli
DH5O. was constructed.

60

to 9 kb fragments were obtained by centrifugation on a 5%
incremental Sucrose gradient with a range of 10 to 40%.
After dialysis against TE buffer, the DNA fragments were

ligated with T4 DNA ligase (Stratagene, LaJolla, Calif.) to
plasmid vector puC18 (Bethesda Research Laboratories,
Inc., Gaithersburg, Md.) dephosphorylated with calf intes
tinal alkaline phosphatase (Bethesda Research Laboratories,
Inc., Gaithersburg, Md.). E. coli, strain DH5O. cells were
transformed with the ligation mix and recombinant clones
were Selected by growth on Luria-Bertani (LB) agar con
taining 100 ug/ml amplicillin (Bethesda Research
Laboratories, Inc., Gaithersburg, Md.), 12 tug/ml isopropyl
f3-D-thiogalactosidase (IPTG) (Bethesda Research
Laboratories, Inc., Gaithersburg, Md.), and 40 ug/ml
5-bromo-4-chloro-3-indoyl-f-D-galactoside (X-gal)
(Bethesda Research Laboratories, Inc., Gaithersburg, Md.).
Replica plating was executed by transferring colonies to
nitrocellulose membranes (HAFT, 0.45 um pore size)
(Millipore Corp., Bedford, Mass.).
Transformed E. coli DH5a cells were screened with

65

monoclonal antibodies, such as 10G6/G10, by colony
immunoblotting. These monoclonal antibodies can be pre
pared as described in Example VI or are available from Dr.
Duhamel, University of Nebraska, Lincoln, Nebr. A mono
clonal antibody used for Screening has been designated

5,869,630
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4,000 DNA sequencer (Li-Cor, Inc. Lincoln, Nebr.).

10G6/G10 and is an IgM antibody that is specific for cell
free Supernatants derived from S. hyodysenteriae. Briefly,

Sequencing data were analyzed and assembled using the
Program manual for the GCG Package Version 7, Apr. 1991

replica membranes (Millipore cat. #HATF13750, Millipore
Corp., Bedford, Mass.) were lysed in chloroform vapor

from the Genetics Computer Group (1991). Results are

followed by overnight incubation in lysis/blocking solution

shown in FIG. 1.

(5% nonfat dry milk, 0.5M MgCl, 40 mg/ml lysozyme, 100
mg/ml chloramphenicol, 2 mg/ml DNase) at room tempera
ture. Membranes then were incubated Sequentially at room
temperature with ascites fluid for 2 hours, followed by

biotin-labeled goat anti-mouse IgA+IgG+IgM(H+L) anti
body (Kirkegaard and Perry Laboratories Inc., Gaithersburg,
Md.) for 1 hour, peroxidase-labeled Streptavidin (Kirkegaard
and Perry) for 45 minutes, and 4-Chloro-1-Naphthol
(Kirkegaard and Perry) for 5 minutes. Five 5-minute washes
with wash buffer (1M Tris-base, 2M NaCl, 5% nonfat dry
milk and 0.05% NP-40 (pH 7.5)) were performed between

1O
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Bacteriol, 174:3423-3428 (1992). The sequence encodes a

each incubation Step. One immunopositive clone, designated
pRED3C6, was identified based on development of a dark
purple precipitate.

polypeptide with a predicted molecular weight of a 56 kDa
protein. The nucleotide Sequence may also encode related
polypeptides of Smaller molecular weight that could be
post-translationally processed.
Furthermore, comparisons of the DNA sequence of the
recombinant 2.3-kb DNA fragment of pRED3C6 with the

EXAMPLE III

DNA Sequencing and Primer Selection
The immunopositive clone was amplified and the plasmid
DNA with insert was isolated and sequenced. The insert was
identified as about a 2.3 kb HindIII partial digest fragment.
The nucleotide Sequence of the 2.3 kb insert fragment was
used to design primers.
1. Plasmid and insert DNA isolation and Sequencing

The recombinant plasmids were isolated (MagicTM
Minipreps, Promega Corp., Madison, Wis.), digested with
the restriction enzyme HindIII (GIBCO-BRL), and the DNA
fragments separated by electrophoresis in a 0.8% agarose gel
using TAE running buffer (16 mM Tris-base, 8 mM sodium
acetate, and 1 mM EDTA, pH 7.5) containing 0.66 ug of
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ethidium bromide per ml. The resulting bands were visual
ized and photographed under ultraViolet light with a
Polaroid MP 4 land camera. Recombinant DNA bands were

excised from the gels with a razorblade, isolated (Geneclean
II, BioRad, Richmond, Calif.), and subjected to the restric
tion enzymes AccI, AluI, EcoRI, DraI, Hae|II, SspI and Xbal
(GIBCO-BRL). Resulting fragments were purified and Sub
cloned into the vector pUC18 for Sequencing using a Model

Presence of -10 and -35 sequences along with a probable
ribosomal binding site upstream from the transcription Start
codon of the gene Suggested a single protein transcript.
Analysis of the deduced amino acid sequence of the ORF for
prediction of a membrane translocation Signal failed to
identify any significant homology with other known
N-terminal export Signal Sequences. However, the
C-terminal Sequence of the gene contained a highly charged
amino acid followed by a Ser Thr-rich amphophilic region
Suggestive of an extracellularly Secreted protein. Lory, J.
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Sequences of the tly A gene (Muir et al., Infect. Immun.,
60:529–535 (1992)), tiy B, and tly C gene of S. hyodysen
teriae (A. Agnes H. M. ter Huurne, Ph.D. Dissertation,
University of Utrecht, Utrecht, Netherlands, (1993)), and the
fla A gene of Koopman et al., Inf and Imm., 60:2920 (1992)

indicated that these Sequences had less than 45% nucleotide
Sequence identity and less that 25% amino acid identity. The
nucleotide and amino acid Sequences were also compared
with nucleotide Sequences encoding a 39 kDa protein from
S. hyodysenteriae, shown in ML Technology Ventures’ PCT
Application No. WO91/04036 published Apr. 4, 1991, and
had less than 47% DNA sequence identity and less than 25%
amino acid identity. A comparison to Sequences published in
EP0350715 also showed less than 45% DNA sequence
identity and less than 20% amino acid identity. The nucle
otide Sequence comparison also revealed in most cases that
there were little or no regions of contiguous Sequence
identity of greater than 10 base pairs. The Sequence com
parisons were conducted using GCG Package, version 7.3,

Jun. 1993 (Genetics Computer Group, Madison Wis.). See
Table II.
TABLE II

Sequence analysis comparisons between
the 2.3-kb fragment of clone prED3C6 and sequences currently available.t
Amino acid

Nucleotide

Sequence

Gene

%. Similarity

96 Identity

Muir et al., 1992
Ter Huurne et al., 1993
Ter Huurne et al., 1993
Koopman et al., 1993
ML Tech. Vent, 1991

tly A
tly B
tly C

55.7
45.4
42.O

24.4
19.9
19.5

44.5
42.2
44.4

8
16
2O

fla A

42.6

14.8

44.1

11

Copy #1
Copy #2
Copy #3
Copy #4
Copy #5
Copy #6
Copy #7
Copy #8

42.9
47.1
44.7
43.3
42.9
42.8
42.9
43.7

18.2
19.9
19.8
17.2
19.0
18.8
21.6
19.8

44.6
43.2
44.4
43.6
43.1
41.2
45.O
46.5

ML Tech. Vent, 1990

38 kDa
60 kDa

46.0
43.6

17.0
18.4

42.O
41.7

96 Identity GAPs

iCap, In: Genetics Computer Group. 1991. Program Manual for the GCG Package, Version 7.3,
June 1993, 575 Science Drive, Madison, Wisconsin 53711, p. 5-27 to 5–53.
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Additionally, an exhaustive search of the EMBL database
failed to identify any sequence with significant DNA or
amino acid homology with the recombinant 2.3 kb HindIII
DNA fragment and its deduced amino acid Sequence.
While not meant to limit the invention in any way, there
is evidence that the 56 kDa polypeptide encoded by the
recombinant 2.3 kb DNA fragment of pRED3C6 represents
a putative S. hyodysenteriae hemolysin distinct from those
described previously. This evidence indicates that transfor
mation of a non-hemolytic E. coli host with pRED3C6
conferred hemolytic activity to the E. coli host. Cleavage
and subcloning of the ORF of the recombinant 2.3 kb DNA
fragment resulted in complete loSS of hemolytic activity of
the E. coli host. The fact that the 2.3 kb DNA sequence
reacts Specifically with all the Serotypes of S. hyodysenteriae
and none of the non-pathogenic intestinal Spirochetes further
indicates that it may be associated with a virulence deter
minant of S. hyodysenteriae Such as hemolysin.
2. Southern blotting
Approximately 2 tug of chromosomal DNA from S. hyo
dysenteriae serotypes 1 to 7, S. innocens isolates B256 and
4/71, WBHIS isolates B359 and B1555a and T. Succinifa
ciens were digested with HindIII, electrophoretically Sepa
rated on a 0.8% agarose gel, and transferred by capillary
diffusion as described by Southern et al., J. Mol. Biol.,

28
(SEQ ID NO:4)) and an internal S. hyodysenteriae-specific
oligo nucleotide
probe
(positive - Sense
5'-TAGGGGCTGCTGTTCTAGCTGTAAATGC (SEQ ID
NO:5)) were designed and synthesized (Integrated DNA
Technologies, INC. Coralville, Iowa) based on results of

15

DNA sequence analysis of the recombinant DNA fragment
of the immunopositive clone pRED3C6. The primers were
used for amplification either of purified chromosomal DNAS
or total DNA extracted by the method described in Example
I and Example V either from normal porcine feces inocu
lated with S. hyodysenteriae cells, or from porcine feces,
porcine rectal Swabs, and porcine colonic mucosal Scrapings
obtained from Swine with clinical an infection caused by S.
hyOdysenteriae.
PrimerS or probes can be designed based on the Sequence
of 2.3 kb HindIII fragment shown in FIG. 1. Primers can be
designed using primer Search algorithms Such as Primer

Detective (Clontech Laboratories, Inc., Palo Alto, Calif.).
Probes can be designed using OLIGO Computer Program
(Rychlik and Rhoades, “A Computer Program for Choosing

Optimal-Oligonucleotides for Filter Hybridization,
Sequencing and In Vitro Amplification of DNA”, Nucleic

Acid Res., 17:8543–8551 (1989) or other commercially
available computer Software with Similar applications.
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EXAMPLE IV

98:503–517 (1975), to nylon membranes (HybondTM-N,
Amersham, Arlington Heights, Ill.). Prehybridization,

Analysis of PCR Products from Several Strains of

hybridization, and washing steps with a recombinant DNA

fragment (2.3 kb) obtained from the immunopositive clone

Bacteria

ing kit (Pharmacia LKB Biotechnology, Piscataway, N.J.)

The primers designed as described in Example III were
used to amplify either purified chromosomal DNA or total
DNA extracted from normal porcine feces inoculated with S.
hyodysenteriae cells or porcine feces, porcine rectal Swabs,
and porcine colonic mucosal Scrapings obtained from Swine
with an infection caused by S. hyodysenteriae. The PCR
products were analyzed by hybridization to an internal probe
as described in Example III.
The DNA was amplified using a hot start PCR as

pRED3C6 labelled with O-P dCTP using an oligolabel
were performed as described by Ramanthan et al., Vet.

Microbiol, 37:53-64 (1993). For slot blot analysis purified

genomic DNAS from cultivable reference isolates of the
order Spirochaetales including S. hyodysenteriae Serotypes 1
through 9, S. innocens isolates B256 and 4/71, 16 isolates of
WBHIS belonging to 3 genotypic groups distinct from S.
innocenS, Spirochaeta aurantia, Treponema spp., Borrelia
burgdorferi, and representatives of each of the 10 genetic
groups of the family Leptospiraceae, as well as enteric
bacteria including Escherichia coli, Salmonella spp.,
Campylobacter spp., and Bacteroides vulgatus were applied

35

40

all containing 4 mM MgCl2, 1x of PCR buffer; 0.2 mM of

each DATP, dCTP, dGTP, dTTP (Perkin-Elmer Cetus): 75

to nylon membranes (Zeta-probe TM, Bio-Rad) using a
microfiltration apparatus (Bio-Dot SF(R), Bio-Rad).

Prehybridization, hybridization and washing steps with a
recombinant DNA fragment obtained from the immunopo

pmol of primers; and 1.5 U of Taq DNA polymerase

45

sitive clone pRED3C6 labelled with o-'P dCTP were

V/cm and stained with ethidium bromide. Southern blots

37:53-64 (1993). The results are shown in FIG. 2.

50

kb fragment from clone pRED3C6 yielded a strong hybrid
ization signal with chromosomal DNA from reference iso
lates of S. hyodysenteriae serotypes 1 through 7, but not with

and B1555a, and T. Succinifaciens (FIG. 2). When the same

An oligonucleotide primer pair (positive-sense
5'-GGTACAGGCGGAAACAGACCTT (SEQ ID NO:3)
and negative-sense 5'-TCCTATTCTCTGACCTACTG

were prehybridized and hybridized each for 1 hour at
T-10 C. with an internal S. hyodysenteriae-specific oli

gonucleotide probe 5'-end labelled withy-PATP using T4

polynucleotide kinase (Pharmacia) as described by Maniatis
et al., Molecular Cloning. Laboratory Manual, Cold Spring

S. innocens isolates B256 and 4/71, WBHIS isolates B359

probe was reacted with chromosomal DNAS obtained from
other cultivable reference isolates of the order Spirocha
etales as well as enteric bacteria including Escherichia coli,
Salmonella spp., Campylobacter spp., and Bacteroides Vul
gatus in a slot blot hybridization assay, a Specific Signal was
observed only with chromosomal DNA obtained from ref
erence isolates of S. hyodysenteriae Serotypes 1 through 9.
3. Primers and internal probe for PCR and Southern blot
analysis

(Perkin-Elmer Cetus) in sterile filtered autoclaved water.
Initial denaturing was for 60 S at 95 C., followed by 30
cycles (60s at 65° C. and 120s at 72° C.). The amplified
products were visualized in 1.25% agarose gels ran at 3

carried out as described Ramanthan et al., Vet. Microbiol.,

Southern blot hybridization of o-'PdCTP labelled 2.3-

described by the manufacturer (GeneAmpTM PCR System
480, Perkin Elmer, Norwalk, Conn.) in a total volume of 75

55

Harbor Laboratory, Cold Spring Harbor, N.Y. (1982).
Washes consisted of 1x SSPE (3.6M NaCl, 0.2M NaH2PO,
0.02M EDTA, pH 7.7) with 0.1% SDS (3 times for 5 min at
room temperature and once for 5 min at T-10 C.). The
membranes were exposed to X-OMATAR Cronex radio

60

graph film (Eastman Kodak Company, Rochester, N.Y.) in a
cassette with lightning plus intensifying Screens (DuPont,
Wilmington, Del.) at -70° C.
With purified chromosomal DNA from each of the 9
Serotypes of S. hyodysenteriae as template, PCR assay

65

resulted in 1.55 kb products (FIG. 3). The specificity of the

1.55 kb products for S. hyodysenteriae was confirmed based
on production of a restriction endonuclease pattern of the

5,869,630
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PCR products identical to the predicted restriction map

premises where clinical Signs of an infection caused by S.
hyOdysenteriae were reported by the referring veterinarians

analysis of pRED3C6 (data not shown) and positive hybrid

ization signal with the S. hyodysenteriae-specific internal

(Duhamel et al., J. Vet. Diagn. Invest., 4:285-292 (1992)),

oligonucleotide probe (FIG. 3). The specificity of the reac

were processed for PCR assays and cultures. For PCR
assays, total DNA was extracted from 100 ul of Supernatants
from either dysenteric porcine feces or porcine colonic
mucosal Scrapings, as described above. Rectal Swabs were

tion for S. hyodysenteriae was further confirmed by the
absence of products and hybridization signal, respectively
after gel electrophoresis and Southern blot hybridization
with internal S. hyodysenteriae-specific oligonucleotide
probe of PCR amplified chromosomal DNA obtained from

mixed with 1 ml of sterile PBS for 2 minutes, and the total

DNA was extracted from the Supernatants.
Negative controls were included in all PCR assays for
detection of S. hyodysenteriae in porcine feces. In the Spiked
feces experiments, unspiked feces and feces Spiked with

other cultivable reference isolates of the order

Spirochaetales, including S. innocenS isolates B256 and
4/71, other genotypic groups of WBHIS distinct from S.
innocenS, as well as enteric bacteria including Escherichia
coli, Salmonella spp., Campylobacter spp., and Bacteroides
vulgatus.

10° dilution of broth culture (100-fold dilution beyond the
15

counting chamber) were used as negative controls. In the

EXAMPLE V

PCR Detection of S. hyodysenteriae from
Diagnostic Samples
Samples from uninfected and infected Swine were evalu
ated by the PCR method for diagnosis of the presence of S.
hyOdysenteriae.
1. PCR detection of S. hyodysenteriae in porcine feces
The sensitivity of the PCR detection of S. hyodysenteriae
in porcine feces was determined by two Separate methods. In
a first method, 10-fold serial dilutions of spirochete broth

experiments using fecal Samples from Swine at the onset of
an infection caused by S. hyodysenteriae, dilutions beyond

10' were considered as negative controls (according to
dysenteric feces contain between 10° and 10' CFU/g). In
Kunkle et al., J. Clin. Microbiol., 26:2357–2360 (1988),

the experiments testing diagnostic Specimens, the fecal
sample containing a WBHIS was used as the negative
control.
25

cultures were added to constant Volumes of undiluted nor

and 10 organisms per 0.1 g of feces in the Second experiment

(FIG.3). The number of spirochetes in dysenteric feces from

2 untreated Swine were comparable to those reported pre

viously for the BJ selective culture medium; 1x10 and
2x10 CFU/0.1 ml, respectively. Kunkle et al., J. Clin.

containing either sterile PBS (negative control) or serial

35

sterile PBS, from 10 to 10° and vortexed for 5 minutes.

The samples were allowed to stand for 10 minutes, then the

Supernatant (approximately 0.9 ml) was drawn off and
processed for total DNA extraction as described by the

manufacturer (Nucleon DNA extraction kit, Scotlab,
Shelton, Conn.) except that the samples were heated at 100

C. for 15 min prior to the cell lysis step and 5M sodium
perchlorate deproteinization was replaced by 100 ug of
proteinase Kper ml. Total DNA from each tube was used for
PCR amplification followed by agarose gel electrophoresis
and Southern blot analysis using the S. hyodysenteriae
Specific oligonucleotide probe.

45

In a Second method, feces collected from two untreated
50

volumes of sterile PBS. One-ml fractions from each dilution

then were processed for determination of the total numbers
of viable S. hyodysenteriae by a plate counting method, and
detection of S. hyodysenteriae-specific products by the PCR
assay, respectively. For the plate counting method, a total of
10 drops of 10 ul each were placed onto freshly made BJ
Selective medium, and the number of colony forming units

Porcine feces (n=3), porcine rectal Swabs (n=2), and porcine
colonic mucosal Scrapings (n=4) obtained from six different

hyOdysenteriae-specific products at dilutions up to 10-9 in
both fecal specimens by PCR assay indicated a 1,000 fold
increase in Sensitivity compared with conventional culture.
The 10-1 to 10-12 dilutions yielded negative results by both
Examination of porcine feces, porcine rectal Swabs, and
porcine colonic mucosal Scrapings obtained from nine Swine
on six different premises by PCR assays yielded 1.55-kb
products in all Samples where S. hyodysenteriae was iden
tified by conventional bacteriological culture method, as
shown in Table III below. The one sample which was
negative by PCR assay yielded WBHIS by culture. Table III
shows a comparison of conventional bacteriological culture
method on Selective BJagar medium and polymerase chain

reaction (PCR) assay for detection of Serpulina hyodysen
teriae in diagnostic Specimens.

TABLE III
Sample

Result

55

(CFU) per 0.1 ml was determined after incubation at 42 C.
in the Gas Pak Anaerobic System (BBL) for 9 days. One ml
fractions from each ten-fold dilution were processed for total
DNA extraction, and PCR detection of S. hyodysenteriae, as
described above. The specificity of the PCR assay for
detection of S. hyodysenteriae in diagnostic Specimens was
compared with conventional bacteriological culture on BJ
medium incubated anaerobically at 42 C. for 10 days.

Microbiol., 26:2357–2360 (1988). Presence of S.

methods.
40

Swine at the onset of an infection caused by S. hyodysente

riae were serially diluted ten-fold (10 to 10') in 2 ml

The sensitivity of the PCR assay for detection of S.
hyOdysenteriae in Serial ten-fold dilutions of Spirochete
broth cultures added to normal porcine feces was 1 organism

per 0.1 g of feces in the first experiment (data not shown),

mal porcine feces in two Separate experiments. The Sensi
tivity of the PCR assay was estimated based on the numbers
of Spirochete cells in the original culture as determined by a
Petroff-Houser cell counting chamber. Briefly, sterile tubes
containing 0.1 g of normal feces were inoculated with 1 ml
ten-fold dilutions of S. hyodysenteriae isolate B204 cells in

numbers of spirochetes estimated by the Petroff-Houser cell

60
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Premises

Number

Type

Culture

A.
B
C
D
E

1.
2
1.
1.
1.
2

Feces
RSir
MS
MS
MS
Feces

S.
S.
S.
S.
S.
S.

F

1.

MS

WBHS

Total:

6

9

RS = Porcine rectal swab.

MS = Porcine colonic mucosal scraping.

hyodysenteriae
hyodysenteriae
hyodysenteriae
hyodysenteriae
hyodysenteriae
hyodysenteriae

PCR
-------
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EXAMPLE VI

Shedding patterns by Subclinically-infected Swine including
those on medication as described below.

Preparation of Monoclonal Antibodies to S.
hyOdysenteriae Antigens
Monoclonal antibodies were raised against cell-free
Supernatant antigens from S. hyodysenteriae produced by a

1. Define the pattern and identify the site of S. hyodysente
riae persistence in carrier Swine

About of 20 specific pathogen-free (SPF) swine will be
inoculated with S. hyodysenteriae, isolate B204, as previ
ously described. Elder et al., cited Supra. Each Swine will be
monitored daily for clinical Signs of an infection caused by

previously described method (Dupont et al., in press)
according to Standard methods (Hugo et al., J. Clin.
Microbiol., 25:26-30 (1987)). Polyclonal antibodies were

raised against two different Synthetic peptides Selected from
the predicted amino acid Sequence of the 2.3 kb insert of
clone pRED3C6.
1. Monoclonal antibody production
Eight- to ten-week old BALB/c mice were immunized
intraperitoneally with 100 lug of cell-free Supernatant anti
gens from S. hyodysenteriae, isolate B204, concentrated 10

S. hyodysenteriae (usually within 14 days post-inoculation).

At least about 30 percent of the Swine most likely will die
or need to be euthanatized because of Severe clinical Signs.
The remaining naturally-recovered Swine will be randomly
allocated to two experimental groupS and housed in Separate
15

Department of Veterinary and Biomedical Sciences.
The pattern of S. hyodysenteriae Shedding in naturally

times using a YM5 Diaflow ultrafilter (Amicon, Beverly,
Mass.) and mixed with equal volumes of Freund's complete
adjuvant. Dupont et al., Vet. Microbiol., in press (VETMIC
723). Identical booster injections containing 50 lug of cell

free Supernatant antigens in Freund's incomplete adjuvant
were given 14, 28, and 42 days later. Four days after the
booster injection, Spleen cells were harvested and fused with
SP 2/0 cells using 50% polyethylene glycol. Hybridomas
producing antibodies that reacted with cell-free Supernatant
antigens from S. hyodysenteriae, isolate B204, by ELISA
were cloned by limiting dilution and stabilized before injec
tion into mice for asciteS production. Hugo et al., J. Clin.

recovered Swine (continuous versus sporadic) will be
assessed using the PCR assay described in Example V, and
bacterial culture of fecal Specimens collected every other
day for 30 days from the day of cessation of bloody diarrhea

(usually 14 to 21 days after the onset of clinical signs). At
25

Microbiol., 25:26-30 (1987). Monoclonal antibodies 467,

F11, 1D8/E11, 3E1D/F1, 6C1D/F8 and 10G6/G10 were

identified and are available from Dr. Duhamel, University of
Nebraska, Lincoln, Nebr. Hybridoma 10G6/G10 producing
an IgM monoclonal antibody that reacted with cell-free
Supernatant antigens of S. hyodysenteriae by ELISA was
cloned by limiting dilution and stabilized before injection

35

into mice for asciteS production (Hugo et al., cited Supra)
40

45

guinea pigs. Hopp et al., Mol. Immunol., 20:483 (1983).

Polyclonal antibodies were produced in adult Hartley
Albino guinea pigs against Synthetic peptides A
fragment of clone pRED3C6. The initial injection consisted
of 50 tug of each peptide diluted in 100 ul of sterile water and
mixed with 100 ul of Freund's complete adjuvant adminis
tered Subcutaneously. Booster injections containing 100 lug
of each peptide in 100 ul of sterile water mixed with equal
Volumes of Freund's incomplete adjuvant were given 14 and
28 days after the initial injection. Final bleeding was com
pleted 7 days after the last booster injection.

50
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EXAMPLE VII

Identification of the Site of S. hyodysenteriae
Persistence in Carrier Swine
65

A PCR test may be used for Screening replacement Stock
and during herd elimination programs by analyzing fecal

culture. Duhamel et al., J. Vet. Diag. Invest., 4:285 (1992)
Samples (live Swine) and mucosal Scrapings (necropsy
Specimens) obtained from each Swine will be Subjected to

Lincoln, Nebr.

(DPAKASRPFD) and B (IPLFEALKPKT) derived from the
predicted amino acid sequence of nucleotides 500-529
(peptide A) and 2093–2126 (peptide B) of the 2.3 kb

the end of 30 days, the effect of stress on fecal shedding of
the spirochetes will be determined. Swine from one experi
mental group will be taken for a 40-mile truck-ride, placed
into a disinfected room of the ARF, and the pattern of S.
hyodysenteriae fecal shedding will be monitored for an
additional 7 days.
At the end of the observation period, the Swine in each
group will be euthanatized and the distribution of S. hyod
ySenteriae in 15 predetermined sites along the wall of the
distal ileum, cecum, spiral colon, descending colon, and
rectum of each Swine will be determined by PCR and
and Elder et al., cited Supra. DNA extracted from fecal

and is available from Dr. Duhamel, University of Nebraska,
2. Polyclonal antibodies to synthetic peptides
Information on the predicted amino acid Sequence
encoded by the 2.3 kb fragment of clone pRED3C6 provides
a basis for identification of antigenic domains. Using Hopp
Woods hydrophobicity plots as an indicator of surface
orientation and potential antigenicity, two peptides were
Synthesized and used for production of hyperimmune Sera in

isolation rooms of the Pig Research Facility (ARF) of the

PCR amplification followed by agarose gel electrophoresis
and Southern blot analysis using the S. hyodysenteriae
Specific oligonucleotide probe, as described in Examples IV
and V. Results of PCR assay will be compared with con
ventional bacterial anaerobic culture and will provide an
indication of the site of S. hyodysenteriae levels in feces and
tissueS of the Swine over time post-infection.
2. Analysis of the pattern of S. hyodysenteriae Shedding in
feces of medicated Swine
A total of 30 SPF Swine will be infected with S.

hyOdysenteriae, isolate B204. At the onset of clinical Signs,
Swine will be randomly allocated to five experimental
groups of 5 Swine each and medicated with the following
antimicrobials: Group 1. Carbadox: 50 g/t in feed continu
ous; Group 2. Tiamulin: 3.5 mg/lb/day in water for 5 days;
Group 3.35 g/t in feed continuous; Group 4. Lincomycin: 3.8
mg/lb/day in water for 6 days; Group 5. 100 g/t in feed
continuous. The pattern of S. hyodysenteriae fecal Shedding
will be monitored using PCR and bacterial culture every
other day for 3 weeks after the initiation of medication. At
the end of the observation period, the Swine will be eutha
natized and the presence of S. hyodysenteriae in the intes
tinal tract of each Swine will be determined by PCR and
culture. Results will show the efficacy of the treatment
regimens to decrease infection with S. hyodysenteriae even
to very low levels of invention that can be detected by PCR
methods.
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GAT

TT G

GCA

As p

Le ul Al

a

AAT
As in
48 5

ATT
I e

T CA.
S e r

TAT

AAA

Ty r

Lys

ATA
I e
4 9 O

CTA

AAA

Le u

L y s G 1 y Ty r

GGA

TAT

AAA

Ly

S

TTT
Ph e

GCC
A 1 a
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TAGA GAA GT T

TAC GA C C CTA

AA CAAAAAGA

ATTAGAATTC

TAC GCTA AAA

GAGA G G T AAA

G C C C C C T G CT

C CTA AAA GA G

A G GTA A G CAT

ATTT G CT AGA

AGAT GGTTTA

T G T TTT TATA

C G GAACTTTC

CT CA CAT TAG

TT G T AAT T G G

TAT G CTTTT A

TATAAAAAAG

GATT CTTTAA

TAA TATA C CA

TTA TTT GAA G

CTTT AAA GCC

TAAAACA GAT

GT TATA GT AA

AAA TT AATAA

T G CT GAATTC

GT TAATGAT G

CA GT AAT TAC

AACTATA GAA

C T C GAAAA TT

CAAAT TATAC

TAATT C T GAA

AG TAT AGAAA

CA CTA A GAA G

TT ATTTTT CA

TT G T A CAAAA

AT AGAAAA TT

AAT AT TTACA

G G CAATCG TT

CTTTT AATAA

TATA AGATT C

C CAG TAG GT C

A GA GAAT AG G

ATT CAATTT

( 2) INFORMATION FOR SEQ ID NO:2:
( i) SEQUENCE CHARACTERISTICS:
( A ) LENGTH: 497 amino acids
( B) TYPE: amino acid
( D) TOPOLOGY: linear
i i ) MOLECULETYPE: protein
( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:2:
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( 2) INFORMATION FOR SEQ ID NO:3:
( i) SEQUENCE CHARACTERISTICS:
( A ) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C)STRANDEDNESS: single
(D) TOPOLOGY: linear
( i i ) MOLECULETYPE: DNA (genomic)
( xi ) SEQUENCE DESCRIPTION: SEQ ID NO:3:
G G T ACA G G C G

GAA ACA GA C C

TT

2 2

( 2) INFORMATION FOR SEQ ID NO:4:
( i) SEQUENCE CHARACTERISTICS:
( A ) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C)STRANDEDNESS: single
(D) TOPOLOGY: linear
( i i ) MOLECULETYPE: DNA (genomic)
( xi ) SEQUENCE DESCRIPTION: SEQ ID NO:4:
T C CTATT C T C

T G A C C T ACT G

( 2) INFORMATION FOR SEQ ID NO:5:

2 O

5,869,630
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-continued

( i) SEQUENCE CHARACTERISTICS:
( A ) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C)STRANDEDNESS: single
(D) TOPOLOGY: linear
( i i ) MOLECULETYPE: DNA (genomic)
( xi ) SEQUENCE DESCRIPTION: SEQ ID NO:5:
TAGGG G C T G C

T G TT CTA G CT

G T AAA T G C
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What is claimed is:

1. An isolated HindIII DNA fragment of about 2.3 kb
derived from chromosomal DNA of S. hyodysenteriae B204
comprising the nucleotide sequence of SEQ ID NO:1.
2. An oligonucleotide probe that Specifically hybridizes
under Stringent conditions to a target DNA sequence of S.
hyOdysenteriae, wherein the target Sequence is about a 2.3
kb HindIII partial digest restriction fragment of S. hyodys
enteriae B204 which target DNA sequence comprises SEQ
ID NO:1 and wherein the probe does not hybridize to at least
one other microorganism.
3. The oligonucleotide probe according to claim 2, labeled
with a detectable moiety Selected from the group consisting
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5'-GGTACAGGCGGAAACAGACCTT (SEQ ID NO:3),
or negative Sense

5-TCCTATTCTCTGACCTACTG (SEQ ID NO:4), or

complements thereof.
11. A kit for use in the detection of S. hyodysenteriae in
a biological Sample, comprising:

(a) a first reagent comprising at least one oligonucleotide
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of a biotin labeled nucleotide, radiolabeled nucleotide and a

fluorescent tagged nucleotide.
4. The oligonucleotide probe according to claim 2,
wherein the probe is hybridizable to DNA amplification
products of primers that Specifically hybridize under Strin
gent conditions to the about 2.3 kb HindIII partial digest
restriction fragment of S. hyodysenteriae B204 which
restriction fragment comprises SEQ ID NO:1 and which
primers do not hybridize to at least one other microorgan
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S.

5. The oligonucleotide probe according to claim 2,
wherein the probe is about 20 to 2300 nucleotides long.
6. A recombinant DNA expression vector comprising a
2.3 kb HindIII partial digest restriction fragment of S.
hyodysenteriae B204 which restriction fragment comprises
SEQ ID NO:1 operably linked to transcriptional and trans
lational control regions of the expression vector.
7. An expression vector according to claim 6 having the
characteristics of a plasmid pRED3C6, ATCC No. 75826.
8. A transformed cell carrying a recombinant expression
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primer that specifically hybridizes under Stringent con
ditions to a target Sequence of a 2.3 kb HindIII partial
digest restriction fragment of S. hyodysenteriae B204
which restriction fragment comprises SEQ ID NO: 1
and which primers do not hybridize to at least one other
microorganism.
12. A kit according to claim 11, further comprising in
combination: a Second reagent comprising an oligonucle
otide probe which Specifically hybridizes under Stringent
conditions to either a 2.3 kb HindIII restriction fragment
comprising SEQ ID NO: 1 or to an amplified product
produced using a primer of claim 9 and which probe does
not hybridize to at least one other microorganism; and the
reagents packaged within containing means.
13. The kit according to claim 11, wherein the containing
means are Selected from the group consisting of a Vial, jar,
tubes and multiwell plate.
14. A kit according to claim 11, further comprising
reagents for extracting nucleic acids from a biological
Sample.
15. The kit according to claim 11, wherein the oligonucle
otide primer has a DNA sequence comprising positive Sense

5'-GGTACAGGCGGAAACAGACCTT (SEQ ID NO:3),

vector of claim 6.

9. An oligonucleotide primer for amplifying a target
Sequence of S. hyodysenteriae, wherein the primer Specifi
cally hybridizes under Stringent conditions to a target
Sequence, wherein the target Sequence is a 2.3 kb HindIII
partial digest restriction fragment of S. hyodysenteriae B204
which restriction fragment comprises SEQ ID NO: 1 and
which primer does not hybridize to at least one other
microorganism.

10. The oligonucleotide primer according to claim 9,
wherein the oligonucleotide has a DNA sequence compris
ing positive Sense

or negative Sense

5'-TCCTATTCTCTGACCTACTG (SEQ ID NO:4),
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complements thereof, or mixtures thereof.
16. A kit according to claim 11, further comprising
reagents for conducting the polymerase chain reaction.
17. An isolated nucleic acid consisting of SEQ ID NO: 1.
k
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